RECENT MAJOR CHANGES

1 INDICATIONS AND USAGE

1.1 Rheumatoid Arthritis

Tofacitinib tablets are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), who have had an inadequate response or intolerance to one or more TNF blockers.

Limitations of Use

Use of tofacitinib tablets in combination with biologic disease-modifying antirheumatic drugs (DMARDs) or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

1.2 Psoriatic Arthritis

Tofacitinib tablets are indicated for the treatment of adult and pediatric patients 2 years of age and older with active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to one or more TNF blockers.

Limitations of Use

Use of tofacitinib tablets in combination with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

1.3 Ankylosing Spondylitis

Tofacitinib tablets are indicated for the treatment of adult patients with active ankylosing spondylitis (AS), who have had an inadequate response or intolerance to one or more TNF blockers.

Limitations of Use

Use of tofacitinib tablets in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

1.4 Polyarticular Course Juvenile Idiopathic Arthritis

Tofacitinib tablets are indicated for the treatment of pediatric patients 2 years of age and older with active polyarticular course juvenile idiopathic arthritis (pcJIA), who have had an inadequate response or intolerance to one or more TNF blockers.

Limitations of Use

Use of tofacitinib tablets in combination with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

1.5 Ulcerative Colitis

Tofacitinib tablets are indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have an inadequate response or intolerance to one or more TNF blockers.

Limitations of Use

Use of tofacitinib tablets in combination with biological therapies for UC or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Evaluations and Immunization Prior to Treatment Initiation

Prior to initiating tofacitinib tablets, consider performing the following:

Active and latent tuberculosis (TB) infection evaluation: If the patient has latent TB, treat for TB prior to tofacitinib tablets treatment [see Warnings and Precautions (5.1)]. Viral hepatitis screening in accordance with clinical guidelines [see Warnings and Precautions (5.1)].A complete blood count: Avoid initiation of tofacitinib tablets treatment in patients with a lymphocyte count less than 500 cells/mm³, absolute neutrophil count less than 1,000 cells/mm³, or hemoglobin level less than 9 g/dL [see Warnings and Precautions (5.8)]. Baseline hepatic function evaluation: tofacitinib tablets is not recommended for patients with severe hepatic impairment [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]. Update immunizations according to current immunization guidelines. The interval between live vaccinations and initiation of tofacitinib tablets should be in accordance with current vaccination guidelines regarding immunosuppressive agents [see Warnings and Precautions (5.9)].

2.2 Important Administration Instructions

XELJANZ XR (extended-release tablets) is not substitutable with tofacitinib tablets. Switching between tofacitinib tablets and XELJANZ XR should be made by the healthcare provider. Dose interruption is recommended for management of lymphopenia, neutropenia, and anemia [see Warnings and Precautions (5.8) and Adverse Reactions (6.1)]. Interrupt use of tofacitinib tablets if a patient develops a serious infection until the infection is controlled [see Warnings and Precautions (5.1)]. Take tofacitinib tablets with or without food [see Clinical Pharmacology (12.3)].

2.3 Recommended Dosage in Adults with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

Table 1 displays the recommended dosage of tofacitinib tablets for adults with RA, PsA, and AS [see Indication and Usage (1.1, 1.2, 1.3)] with and without renal impairment (including those who are undergoing hemodialysis) or hepatic impairment [see Use in Specific Populations (8.6, 8.7)]. The table also displays the recommended dosage modifications for patients concomitantly using CYP2C19 and/or CYP3A4 inhibitors [see Drug Interactions (7) and Clinical Pharmacology (12.3)], and patients with lymphopenia, neutropenia, or anemia.

Adults	Tofacitinib Tablets
Patients with Normal Renal and Hepatic Function^a	5 mg twice daily
Recommended Dosage in Patients with Renal Impairment (RI)^b
Mild RI (CLcr > 50 and ≤ 80 mL/min)	5 mg twice daily
Moderate RI (CLcr ≥ 30 and ≤ 50 mL/min)	5 mg once daily
Severe RI (CLcr < 30 mL/min)	5 mg once daily
Severe RI (CLcr < 30 mL/min)	For patients undergoing hemodialysis, administer the dose after the dialysis session on dialysis days. If a dose was taken before the dialysis procedure, supplemental doses are not recommended after dialysis.
Recommended Dosage in Patients with Hepatic Impairment (HI)
Mild HI (Child-Pugh A)	5 mg twice daily
Moderate HI (Child-Pugh B)	5 mg once daily
Severe HI (Child-Pugh C)	Use of tofacitinib tablets is not recommended.
Dosage Modifications with Concomitant Use of CYP3A4 and/or CYP2C19 Inhibitor(s)
Strong CYP2C19 inhibitor(s)	5 mg twice daily
Moderate CYP2C19 inhibitor(s)
Moderate CYP3A4 inhibitor(s)
Moderate CYP3A4 inhibitor(s) with strong CYP2C19 inhibitor(s) (e.g., fluconazole)	5 mg once daily
Strong CYP3A4 inhibitor(s)	5 mg once daily
Dosage Modifications for Lymphopenia, Neutropenia, or Anemia
Patients with lymphocyte count less than 500 cells/mm³, confirmed by repeat testing	Discontinue dosing.
Patients with ANC less than 500 cells/mm³	Discontinue dosing.
Patients with ANC 500 cells/mm³ to 1,000 cells/mm³	Interrupt dosing. When ANC is greater than 1,000, resume 5 mg twice daily.
Patients with hemoglobin less than 8 g/dL or a decrease of more than 2 g/dL	Interrupt dosing until hemoglobin values have normalized.

^a Excludes patients who concomitantly use tofacitinib tablets with strong CYP3A4 inhibitor(s) or moderate CYP3A4 inhibitor(s) and strong CYP2C19 inhibitor(s), as well as patients with lymphocyte count less than 500 cells/mm³, ANC < 1,000 cells/mm³, or hemoglobin less than 8 g/dL or a decrease of more than

2 g/dL.

^b Tofacitinib PK was evaluated in subjects with varying degrees of renal impairment, where the severity of renal impairment was defined based on creatinine clearance (CLcr) estimated using the Cockcroft-Gault equation: CLcr > 80 mL/min (normal renal function); > 50 and

≤ 80 mL/min (mild renal impairment); ≥ 30 and ≤ 50 mL/min (moderate renal impairment);

< 30 mL/min (severe renal impairment).

Switching from Tofacitinib Tablets to XELJANZ XR Extended-Release Tablets

Patients treated with tofacitinib tablets 5 mg twice daily may be switched to XELJANZ XR extended-release tablets 11 mg once daily the day following the last dose of tofacitinib tablets 5 mg.

2.4 Recommended Dosage in Pediatric Patients 2 Years of Age and Older with Psoriatic Arthritis or Polyarticular Course Juvenile Idiopathic Arthritis

Table 2 displays the recommended body weight-based dosages for tofacitinib tablets in pediatric patients 2 years of age and older with PsA or pcJIA [see Indication and Usage (1.2, 1.4)] with and without renal impairment (including those who are undergoing hemodialysis) or hepatic impairment [see Use in Specific Populations (8.6, 8.7)]. The table also includes recommended dosage modification for pediatric patients concomitantly using CYP2C19 and/or CYP3A4 inhibitors [see Drug Interactions (7) and Clinical Pharmacology (12.3)], and pediatric patients with lymphopenia, neutropenia, or anemia.

Pediatric Patients 2 Years of Age and Older	Tofacitinib tablets
Patients with Normal Renal and Hepatic Function^a	Body weight ≥ 40 kg: 5 mg (one 5 mg tablet or 5 mL oral solution) twice daily^b
Recommended Dosage in Patients with Renal Impairment (RI)
Mild RI	Same as patients with normal renal function.
Moderate RI	Body weight ≥ 40 kg: 5 mg once daily^b
Severe RI	Body weight ≥ 40 kg: 5 mg once daily^b
Severe RI	For patients undergoing hemodialysis, administer the dose after the dialysis session on dialysis days. If a dose was taken before the dialysis procedure, supplemental doses are not recommended after dialysis.
Recommended Dosage in Patients with Hepatic Impairment (HI)
Mild HI	Same as patients with normal hepatic function.
Moderate HI	Body weight ≥ 40 kg: 5 mg once daily^b
Severe HI	Use of tofacitinib tablets is not recommended.
Dosage Modifications with Concomitant Use of CYP3A4 and/or CYP2C19 Inhibitor(s)
Strong CYP2C19 inhibitor(s)	No dosage modification is recommended.
Moderate CYP2C19 inhibitor(s)
Moderate CYP3A4 inhibitor(s)
Moderate CYP3A4 inhibitor(s) with strong CYP2C19 inhibitor(s) (e.g., fluconazole)	Body weight ≥ 40 kg: 5 mg once daily^b
Strong CYP3A4 inhibitor(s)	Body weight ≥ 40 kg: 5 mg once daily^b
Dosage Modifications for Lymphopenia, Neutropenia, or Anemia
Patients with lymphocyte count less than 500 cells/mm³, confirmed by repeat testing	Discontinue dosing.
Patients with ANC less than 500 cells/mm³	Discontinue dosing.
Patients with ANC 500 to 1,000 cells/mm³	Interrupt dosing until ANC is greater than 1,000 cells/mm³.
Patients with hemoglobin less than 8 g/dL or a decrease of more than 2 g/dL	Interrupt dosing until hemoglobin values have normalized.

^a Excludes patients who concomitantly use tofacitinib tablets with strong CYP3A4 inhibitor(s) or moderate CYP3A4 inhibitor(s) and strong CYP2C19 inhibitor(s), as well as patients with lymphocyte count less than 500 cells/mm³, ANC < 1,000 cells/mm³, or hemoglobin less than 8 g/dL or a decrease of more than 2 g/dL.

^b Patients treated with XELJANZ oral solution 5 mL may be switched to tofacitinib tablets 5 mg.

2.5 Recommended Dosage in Adults with Ulcerative Colitis

Table 3 displays the recommended dosage of tofacitinib tablets in adult patients with ulcerative colitis (UC) [see Indications and Usage (1.5)] with and without renal impairment (including those who are undergoing hemodialysis) or hepatic impairment [see Use in Specific Populations (8.6, 8.7)]. Table 4 displays the recommended dosage modification for patients concomitantly using CYP2C19 and/or CYP3A4 inhibitors [see Drug Interactions (7) and Clinical Pharmacology (12.3)], and patients with lymphopenia, neutropenia, or anemia.

Adults	Tofacitinib tablets
Patients with Normal Renal and Hepatic Function^a	Induction: 10 mg twice daily for at least 8 weeks [see Clinical Studies (14.5)] ; evaluate patients and transition to maintenance therapy depending on therapeutic response. If needed continue 10 mg twice daily for a maximum of 16 weeks. Discontinue 10 mg twice daily after 16 weeks if adequate therapeutic response is not achieved. Maintenance: 5 mg twice daily. For patients with loss of response during maintenance treatment, may consider a dosage of 10 mg twice daily (limited to the shortest duration), with careful consideration of the benefits and risks for the individual patient. Use the lowest effective dosage needed to maintain response.
Recommended Dosage in Patients with Renal Impairment (RI)^b
Mild RI (CLcr > 50 and ≤ 80 mL/min)	Same as patients with normal renal function.
Moderate RI (CLcr ≥ 30 and ≤ 50 mL/min)	Induction: 5 mg twice daily for at least 8 weeks [see Clinical Studies (14.5)] ; evaluate patients and transition to maintenance therapy depending on therapeutic response. If needed continue 5 mg twice daily for a maximum of 16 weeks. Discontinue 5 mg twice daily after 16 weeks if adequate therapeutic response is not achieved. Maintenance: 5 mg once daily. For patients with loss of response during maintenance treatment, may consider a dosage of 5 mg twice daily (limited to the shortest duration), with careful consideration of the benefits and risks for the individual patient. Use the lowest effective dosage needed to maintain response.
Severe RI (CLcr < 30 mL/min)
	For patients undergoing hemodialysis, administer the dose after the dialysis session on dialysis days. If a dose was taken before the dialysis procedure, supplemental doses are not recommended after dialysis.
Recommended Dosage in Patients with Hepatic Impairment (HI)
Mild HI (Child-Pugh A)	Same as patients with normal hepatic function.
Moderate HI (Child-Pugh B)	Induction: 5 mg twice daily for at least 8 weeks [see Clinical Studies (14.5)] ; evaluate patients and transition to maintenance therapy depending on therapeutic response. If needed continue 5 mg twice daily for a maximum of 16 weeks. Discontinue 5 mg twice daily after 16 weeks if adequate therapeutic response is not achieved. Maintenance: 5 mg once daily. For patients with loss of response during maintenance treatment, may consider a dosage of 5 mg twice daily (limited to the shortest duration), with careful consideration of the benefits and risks for the individual patient. Use the lowest effective dosage needed to maintain response.
Severe HI (Child-Pugh C)	Use of tofacitinib tablets is not recommended.

^a Excludes patients who concomitantly use tofacitinib tablets with strong CYP3A4 inhibitor(s) or moderate CYP3A4 inhibitor(s) and strong CYP2C19 inhibitor(s), as well as patients with lymphocyte count less than 500 cells/mm³, ANC < 1,000 cells/mm³, or hemoglobin less than 8 g/dL or a decrease of more than 2 g/dL.

^b Tofacitinib PK was evaluated in subjects with varying degrees of renal impairment, where the severity of renal impairment was defined based on creatinine clearance (CLcr) estimated using the Cockcroft-Gault equation: CLcr > 80 mL/min (normal renal function); CLcr > 50 and ≤ 80 mL/min (mild renal impairment); ≥ 30 and ≤ 50 mL/min (moderate renal impairment); < 30 mL/min (severe renal impairment).

Adults	Tofacitinib Tablets
Dosage Modifications with Concomitant Use of CYP3A4 and/or CYP2C19 Inhibitor(s)
Strong CYP2C19 inhibitor(s)	No dosage modification is recommended.
Moderate CYP2C19 inhibitor(s)
Moderate CYP3A4 inhibitor(s)
Moderate CYP3A4 inhibitor(s) with strong CYP2C19 inhibitor(s) (e.g., fluconazole)	Induction: 5 mg twice daily for at least 8 weeks [see Clinical Studies (14.5)] ; evaluate patients and transition to maintenance therapy depending on therapeutic response. If needed continue 5 mg twice daily for a maximum of 16 weeks. Discontinue 5 mg twice daily after 16 weeks if adequate therapeutic response is not achieved.
Strong CYP3A4 inhibitor(s)	Maintenance: 5 mg once daily. For patients with loss of response during maintenance treatment, may consider a dosage of 5 mg twice daily (limited to the shortest duration), with careful consideration of the benefits and risks for the individual patient. Use the lowest effective dosage needed to maintain response.
Dosage Modifications for Lymphopenia, Neutropenia, or Anemia
Lymphocyte count less than 500 cells/mm³, confirmed by repeat testing	Discontinue dosing.
ANC less than 500 cells/mm³	Discontinue dosing.
ANC 500 to 1,000 cells/mm³	If taking: ● 10 mg twice daily, reduce to 5 mg twice daily. When ANC is greater than 1,000, increase to 10 mg twice daily based on clinical response. ● 5 mg twice daily, interrupt dosing. When ANC is greater than 1,000, resume 5 mg twice daily.
Hemoglobin less than 8 g/dL or a decrease of more than 2 g/dL	Interrupt dosing until hemoglobin values have normalized.

Switching from Tofacitinib Tablets to XELJANZ XR Extended-Release Tablets

Patients treated with tofacitinib tablets:

5 mg twice daily may be switched to XELJANZ XR extended-release tablets 11 mg once daily the day following the last dose of tofacitinib tablets 5 mg. 10 mg twice daily may be switched to XELJANZ XR extended-release tablets 22 mg once daily the day following the last dose of tofacitinib tablets 10 mg.

3 DOSAGE FORMS AND STRENGTHS

Tofacitinib tablets, 5 mg (equivalent to 8.08 mg tofacitinib citrate) are white to off white colored, round, film-coated tablets, debossed with "1243" on one side and plain on the other side.

Tofacitinib tablets, 10 mg (equivalent to 16.15 mg tofacitinib citrate) are light green to green colored, round shaped, film coated tablets debossed with "1589" on one side and plain on the other side.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Serious Infections

Serious and sometimes fatal infections may occur with tofacitinib tablets. Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving tofacitinib. The most common serious infections reported with tofacitinib included pneumonia, urinary tract infection, cellulitis, herpes zoster, bronchitis, septic shock, diverticulitis, gastroenteritis, appendicitis, and sepsis. Among opportunistic infections, tuberculosis and other mycobacterial infections, cryptococcosis, histoplasmosis, esophageal candidiasis, pneumocystosis, multi−dermatomal herpes zoster, cytomegalovirus infections, BK virus infection, and listeriosis were reported with tofacitinib. Some patients have presented with disseminated rather than localized disease and were often taking concomitant immunomodulating agents such as methotrexate or corticosteroids.

In the UC population, treatment with tofacitinib tablets 10 mg twice daily was associated with greater risk of serious infections compared to 5 mg twice daily. Additionally, opportunistic herpes zoster infections (including meningoencephalitis, ophthalmologic, and disseminated cutaneous) were seen in patients who were treated with tofacitinib tablets 10 mg twice daily.

Other serious infections that were not reported in clinical studies may also occur (e.g., coccidioidomycosis).

Avoid use of tofacitinib tablets in patients with an active, serious infection, including localized infections. The risks and benefits of treatment should be considered prior to initiating tofacitinib tablets in patients:

with chronic or recurrent infection who have been exposed to tuberculosis with a history of a serious or an opportunistic infection who have resided or traveled in areas of endemic tuberculosis or endemic mycoses; or with underlying conditions that may predispose them to infection. Closely monitor patients for the development of signs and symptoms of infection during and after treatment with tofacitinib tablets. Interrupt tofacitinib tablets if a patient develops a serious infection, an opportunistic infection, or sepsis. In patients who develop a new infection during treatment with tofacitinib tablets, promptly complete diagnostic testing appropriate for an immunocompromised patient; initiate appropriate antimicrobial therapy, and monitor the patients closely.

Caution is also recommended in patients with a history of chronic lung disease, or in those who develop interstitial lung disease, as they may be more prone to infections.

Risk of infection may be higher with increasing degrees of lymphopenia and consideration should be given to lymphocyte counts when assessing individual patient risk of infection. Discontinuation and monitoring criteria for lymphopenia are recommended [see Dosage and Administration (2.3, 2.4, 2.5)].

Tuberculosis

Evaluate and test patients for latent or active tuberculosis (TB) infection prior to and per applicable guidelines during administration of tofacitinib tablets.

Consider anti-TB therapy prior to administration of tofacitinib tablets in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent TB but who have risk factors for TB infection. Consultation with a physician with expertise in the treatment of TB is recommended to aid in the decision about whether initiating anti-TB therapy is appropriate for an individual patient.

Monitor patients closely for the development of signs and symptoms of TB, including patients who tested negative for latent TB infection prior to initiating therapy.

Treat patients with latent TB with standard antimycobacterial therapy before administering tofacitinib tablets.

Viral Reactivation

Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), were observed in clinical studies with tofacitinib. Postmarketing cases of hepatitis B reactivation have been reported in patients treated with tofacitinib. The impact of tofacitinib tablets on chronic viral hepatitis reactivation is unknown. Patients who screened positive for hepatitis B or C were excluded from clinical trials. Perform screening for viral hepatitis in accordance with clinical guidelines before starting therapy with tofacitinib tablets. The risk of herpes zoster is increased in patients treated with tofacitinib tablets and appears to be higher in patients treated with tofacitinib in Japan and Korea.

5.2 Increased Risk of Mortality

Increased risk of mortality may occur with tofacitinib tablets. Adult patients with rheumatoid arthritis (RA), 50 years of age and older, with at least one cardiovascular risk factor treated with tofacitinib tablets 5 mg or 10 mg twice a day had a higher observed rate of all-cause mortality, including sudden cardiovascular death, compared to those treated with TNF blockers in a large, randomized, postmarketing safety study (RA Safety Study 1). The incidence rate of all-cause mortality per 100 patient-years was 1.23 for tofacitinib tablets 10 mg twice a day, 0.88 for tofacitinib tablets 5 mg twice a day, and 0.69 for TNF blockers [see Clinical Studies (14.6)]. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with tofacitinib tablets.

Tofacitinib tablets 10 mg twice daily dosages are not recommended for the treatment of RA, PsA, AS, or pcJIA [see Dosage and Administration (2.3, 2.4)].

For the treatment of UC, use tofacitinib tablets at the lowest effective dose and for the shortest duration needed to achieve/maintain therapeutic response [see Dosage and Administration (2.5)].

5.3 Malignancy and Lymphoproliferative Disorders

Malignancies and lymphoproliferative disorders may occur with tofacitinib tablets. Malignancies, including lymphomas and solid cancers, were observed in clinical studies of tofacitinib [see Adverse Reactions (6.1)].

Other malignancies were observed in tofacitinib clinical studies and the postmarketing setting, including, but not limited to, lung cancer, breast cancer, melanoma, prostate cancer, and pancreatic cancer.

In RA Safety Study 1, a higher rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was observed in patients treated with tofacitinib tablets 5 mg or 10 mg twice a day compared with TNF blockers. The incidence rate of malignancies (excluding NMSC) per 100 patient-years was 1.13 for tofacitinib tablets 10 mg twice a day, 1.13 for tofacitinib tablets 5 mg twice a day, and 0.77 for TNF blockers. Patients who are current or past smokers are at additional increased risk [see Clinical Studies (14.6)].

Lymphomas and lung cancers, which are a subset of all malignancies in RA Safety Study 1, were observed at a higher rate in patients treated with tofacitinib tablets 5 mg twice a day and tofacitinib tablets 10 mg twice a day compared to those treated with TNF blockers. The incidence rate of lymphomas per 100 patient-years was 0.11 for tofacitinib tablets 10 mg twice a day, 0.07 for tofacitinib tablets 5 mg twice a day, and 0.02 for TNF blockers. The incidence rate of lung cancers per 100 patient-years among current and past smokers was 0.59 for tofacitinib tablets 10 mg twice a day, 0.48 for tofacitinib tablets 5 mg twice a day, and 0.27 for TNF blockers [see Clinical Studies (14.6)].

Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with tofacitinib tablets, particularly in patients with a known malignancy (other than a successfully treated NMSC), patients who develop a malignancy while on treatment, and patients who are current or past smokers. Tofacitinib tablets 10 mg twice daily dosages are not recommended for the treatment of RA, PsA, AS, or pcJIA [see Dosage and Administration (2.3, 2.4)].

Non-Melanoma Skin Cancer

Non-melanoma skin cancers (NMSCs) have been reported in patients treated with tofacitinib tablets. Periodic skin examination is recommended for patients who are at increased risk for skin cancer. In the UC population, treatment with tofacitinib tablets 10 mg twice daily was associated with greater risk of NMSC than treatment with placebo.

5.4 Major Adverse Cardiovascular Events

Major adverse cardiovascular events may occur with tofacitinib tablets. In RA Safety Study 1, patients with RA who were 50 years of age and older with at least one cardiovascular risk factor and treated with tofacitinib tablets 5 mg or 10 mg twice daily had a higher rate of major adverse cardiovascular events (MACE) defined as cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke, compared to those treated with TNF blockers. The incidence rate of MACE per 100 patient-years was 1.11 for tofacitinib tablets 10 mg twice a day, 0.91 for tofacitinib tablets 5 mg twice a day, and 0.79 for TNF blockers. The incidence rate of fatal or non-fatal myocardial infarction per 100 patient-years was 0.39 for tofacitinib tablets 10 mg twice a day, 0.36 for tofacitinib tablets 5 mg twice a day, and 0.2 for TNF blockers [see Clinical Studies (14.6)].

Patients who are current or past smokers are at additional increased risk.

Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with tofacitinib tablets, particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Inform patients about the symptoms of serious cardiovascular events and the steps to take if they occur. Discontinue tofacitinib tablets in patients that have experienced a MI or stroke. Tofacitinib tablets 10 mg twice daily dosage is not recommended for the treatment of RA, PsA, AS, or pcJIA [see Dosage and Administration (2.3, 2.4)].

5.5 Thrombosis

Thrombosis may occur with tofacitinib tablets. Thrombosis, including pulmonary embolism (PE), deep venous thrombosis (DVT), and arterial thrombosis, have occurred in patients treated with tofacitinib tablets and other Janus kinase (JAK) inhibitors used to treat inflammatory conditions. Many of these events were serious and some resulted in death [see Warnings and Precautions (5.2)].

Patients with RA 50 years of age and older with at least one cardiovascular risk factor treated with tofacitinib tablets 5 mg or 10 mg twice daily compared to TNF blockers in RA Safety Study 1 had an observed increase in incidence of these thrombotic events. The incidence rate of DVT per 100 patient-years was 0.28 for tofacitinib tablets 10 mg twice a day, 0.22 for tofacitinib tablets 5 mg twice a day, and 0.16 for TNF blockers. The incidence rate of PE per 100 patient-years was 0.49 for tofacitinib tablets 10 mg twice a day, 0.18 for tofacitinib tablets 5 mg twice a day, and 0.05 for TNF blockers [see Clinical Studies (14.6)].

Tofacitinib tablets 10 mg twice daily dosage is not recommended for the treatment of RA, PsA, AS, or pcJIA [see Dosage and Administration (2.3, 2.4)].

In a long-term extension study in patients with UC, five cases of pulmonary embolism were reported in patients taking tofacitinib 10 mg twice daily, including one death in a patient with advanced cancer.

Promptly evaluate patients with symptoms of thrombosis and discontinue tofacitinib tablets in patients with symptoms of thrombosis.

Avoid tofacitinib tablets in patients that may be at increased risk of thrombosis. For the treatment of UC, use tofacitinib tablets at the lowest effective dose and for the shortest duration needed to achieve/maintain therapeutic response [see Dosage and Administration (2.5)].

5.6 Gastrointestinal Perforations

Gastrointestinal perforations may occur with tofacitinib tablets. Events of gastrointestinal perforation have been reported in clinical studies with tofacitinib tablets, although the role of JAK inhibition in these events is not known. In these studies, many patients with RA received background therapy with nonsteroidal anti-inflammatory drugs (NSAIDs).

There was no discernable difference in frequency of gastrointestinal perforation between the placebo and the tofacitinib tablets treatment groups in clinical trials of patients with UC, and many of them were receiving background corticosteroids. Promptly evaluate patients treated with tofacitinib tablets who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis or taking NSAIDs) and who present with new onset abdominal symptoms for early identification of gastrointestinal perforation [see Adverse Reactions (6.1)].

5.7 Hypersensitivity Reactions

Hypersensitivity reactions may occur with tofacitinib tablets. Reactions such as angioedema and urticaria that may reflect drug hypersensitivity have been observed in patients receiving tofacitinib tablets. Some events were serious. If a serious hypersensitivity reaction occurs, promptly discontinue tofacitinib tablets while evaluating the potential cause or causes of the reaction [see Adverse Reactions (6.2)].

5.8 Laboratory Abnormalities

Laboratory abnormalities may occur with tofacitinib tablets.

Lymphocyte Abnormalities

Treatment with tofacitinib tablets was associated with initial lymphocytosis at one month of tofacitinib tablets treatment followed by a gradual decrease in mean absolute lymphocyte counts below the baseline of approximately 10% during 12 months of therapy. Lymphocyte counts less than 500 cells/mm³ in these patients were associated with an increased incidence of treated and serious infections.

Monitor lymphocyte counts at baseline and every 3 months thereafter. Avoid initiation of tofacitinib tablets treatment in patients with a low lymphocyte count (i.e., less than 500 cells/mm³). In patients who develop a confirmed absolute lymphocyte count less than 500 cells/mm³, treatment with tofacitinib tablets is not recommended. Neutropenia

Treatment with tofacitinib tablets was associated with an increased incidence of neutropenia (less than 2,000 cells/mm³) compared to treatment with placebo.

Monitor neutrophil counts at baseline and after 4 weeks to 8 weeks of treatment and every 3 months thereafter. Avoid initiation of tofacitinib tablets treatment in patients with a low neutrophil count (i.e., ANC less than 1,000 cells/mm³). For patients who develop a persistent ANC of 500 cells/mm³to 1,000 cells/mm³, interrupt dosing until ANC is greater than or equal to 1,000 cells/mm³. In patients who develop an ANC less than 500 cells/mm³, treatment with tofacitinib tablets is not recommended. Anemia

Monitor hemoglobin at baseline and after 4 weeks to 8 weeks of treatment and every 3 months thereafter. Avoid initiation of tofacitinib tablets treatment in patients with a low hemoglobin level (i.e., less than 9 g/dL). Interrupt treatment with tofacitinib tablets in patients who develop hemoglobin levels less than 8 g/dL or whose hemoglobin level drops greater than 2 g/dL on treatment until hemoglobin values have normalized. Liver Enzyme Elevations

Treatment with tofacitinib tablets was associated with an increased incidence of liver enzyme elevation compared to treatment with placebo. Most of these abnormalities occurred in studies with background DMARD therapy (primarily methotrexate).

Routine monitoring of liver tests and prompt investigation of the causes of liver enzyme elevations is recommended to identify potential cases of drug-induced liver injury. If drug-induced liver injury is suspected, interrupt the administration of tofacitinib tablets until this diagnosis has been excluded. Lipid Elevations

Treatment with tofacitinib tablets was associated with dose-dependent increases in lipid parameters including total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. Maximum changes in these lipid parameters were generally observed within 6 weeks. There were no clinically relevant changes in LDL/HDL cholesterol ratios. The effect of these lipid parameter elevations on cardiovascular morbidity and mortality has not been determined.

Perform assessment of lipid parameters approximately 4 weeks to 8 weeks following initiation of tofacitinib tablets therapy. Manage patients according to clinical guidelines [e.g., National Cholesterol Educational Program (NCEP)] for the management of hyperlipidemia.

5.9 Vaccinations

Avoid use of live vaccines concurrently with tofacitinib tablets. Prior to initiating tofacitinib tablets therapy, update immunizations in agreement with current immunization guidelines. The interval between live vaccinations and initiation of tofacitinib tablets therapy should be in accordance with current vaccination guidelines regarding immunosuppressive agents.

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

Serious Infections [see Warnings and Precautions (5.1)] Increased Risk of Mortality [see Warnings and Precautions (5.2)] Malignancy and Lymphoproliferative Disorders [see Warnings and Precautions (5.3)] Major Adverse Cardiovascular Events [see Warnings and Precautions (5.4)] Thrombosis [see Warnings and Precautions (5.5)] Gastrointestinal Perforations [see Warnings and Precautions (5.6)] Hypersensitivity Reactions [see Warnings and Precautions (5.7)] Laboratory Abnormalities [see Warnings and Precautions (5.8)]

6.1 Clinical Trials Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not predict the rates observed in a broader patient population in clinical practice.

The clinical studies described in this subsection were conducted using tofacitinib tablets (referred to as "tofacitinib" in this subsection of labeling) and/or XELJANZ oral solution.

Adverse Reactions in Adults with Rheumatoid Arthritis

In RA Safety Study 1, 1,455 adults were treated with tofacitinib 5 mg twice daily, 1,456 adults were treated with 10 mg twice daily, and 1,451 adults were treated with a TNF blocker for a median of 4 years [see Clinical Studies (14.6)]. A dosage of tofacitinib 10 mg twice daily is not recommended for the treatment of RA because of increased risks [see Dosage and Administration (2.3) and Warnings and Precautions (5)]. For the treatment of adults with moderately to severely active RA [see Indications and Usage (1.1)], the recommended dosage of tofacitinib is 5 mg twice daily.

The safety of tofacitinib was also evaluated in two Phase 2 and five Phase 3 double-blind, placebo-controlled, multicenter trials in patients with RA. In these trials, adults were randomized to receive:

Tofacitinib (monotherapy) 5 mg twice daily (292 patients) or 10 mg twice daily (306 patients), In combination with DMARDs (including methotrexate), tofacitinib 5 mg twice daily (1,044 patients) or 10 mg twice daily (1,043 patients) and Placebo (809 patients). All seven trials included provisions for patients taking placebo to receive treatment with tofacitinib at Month 3 or Month 6 either by patient response (based on uncontrolled disease activity) or by design, so that adverse events cannot always be unambiguously attributed to a given treatment. Therefore, some analyses that follow include patients who changed treatment by design or by patient response from placebo to tofacitinib in both the placebo and tofacitinib group of a given interval. Comparisons between placebo and tofacitinib groups were based on the first 3 months of exposure, and comparisons between tofacitinib 5 mg twice daily and tofacitinib 10 mg twice daily were based on the first 12 months of exposure.

The long-term safety population includes all adults with RA who participated in a double-blind, placebo-controlled trial (including earlier development phase studies) and then participated in one of two long-term safety studies. The design of the long-term safety studies allowed for modification of tofacitinib doses according to clinical judgment. This limits the interpretation of the long-term safety data with respect to dose.

The most common serious adverse reactions were serious infections [see Warnings and Precautions (5.1)].

The proportion of patients who discontinued treatment due to any adverse reaction during the 0 month to 3 months exposure in the double-blind, placebo-controlled trials was 4% for tofacitinib-treated patients and 3% for placebo-treated patients.

Overall Infections

In the seven placebo-controlled trials in patients with RA, during the 0 month to 3 months exposure, the overall frequency of infections was 20% and 22% in the tofacitinib 5 mg twice daily and tofacitinib 10 mg twice daily groups, respectively, and 18% in the placebo group.

The most commonly reported infections with tofacitinib were upper respiratory tract infections, nasopharyngitis, and urinary tract infections (4%, 3%, and 2% of patients, respectively).

Serious Infections: In the seven placebo-controlled trials in patients with RA, during the 0 month to 3 months exposure, serious infections were reported in 1 patient (0.5 events per 100 patient-years) who received placebo and 11 patients (1.7 events per 100 patient-years) who received tofacitinib 5 mg or 10 mg twice daily. The rate difference between treatment groups (and the corresponding 95% confidence interval) was 1.1 (-0.4, 2.5) events per 100 patient-years for the combined tofacitinib 5 mg twice daily and 10 mg twice daily group minus placebo.

In the seven placebo-controlled trials, during the 0 month to 12 months exposure, serious infections were reported in 34 patients (2.7 events per 100 patient-years) who received tofacitinib 5 mg twice daily and 33 patients (2.7 events per 100 patient-years) who received tofacitinib 10 mg twice daily. The rate difference between tofacitinib doses (and the corresponding 95% confidence interval) was -0.1 (-1.3, 1.2) events per 100 patient-years for tofacitinib 10 mg twice daily minus tofacitinib 5 mg twice daily.

The most common serious infections included pneumonia, cellulitis, herpes zoster, and urinary tract infection [see Warnings and Precautions (5.1)].

Tuberculosis: In the seven placebo-controlled trials in patients with RA, during the 0 month to 3 months exposure, tuberculosis (TB) was not reported in patients who received placebo, tofacitinib 5 mg twice daily, or tofacitinib 10 mg twice daily.

In the seven placebo-controlled trials, during the 0 month to 12 months exposure, TB was reported in 0 patients who received tofacitinib 5 mg twice daily and 6 patients (0.5 events per 100 patient-years) who received tofacitinib 10 mg twice daily. The rate difference between tofacitinib doses (and the corresponding 95% confidence interval) was 0.5 (0.1, 0.9) events per 100 patient-years for tofacitinib 10 mg twice daily minus tofacitinib 5 mg twice daily.

Cases of disseminated TB were also reported. The median tofacitinib exposure prior to diagnosis of TB was 10 months (range from 152 days to 960 days) [see Warnings and Precautions (5.1)].

Opportunistic Infections (excluding tuberculosis): In the seven placebo-controlled trials in patients with RA, during the 0 to 3 months exposure, opportunistic infections were not reported in patients who received placebo, tofacitinib 5 mg twice daily, or tofacitinib 10 mg twice daily.

In the seven placebo-controlled trials, during the 0 month to 12 months exposure, opportunistic infections were reported in 4 patients (0.3 events per 100 patient-years) who received tofacitinib 5 mg twice daily and 4 patients (0.3 events per 100 patient-years) who received tofacitinib 10 mg twice daily. The rate difference between tofacitinib doses (and the corresponding 95% confidence interval) was 0 (-0.5, 0.5) events per 100 patient-years for tofacitinib 10 mg twice daily minus tofacitinib 5 mg twice daily.

The median tofacitinib exposure prior to diagnosis of an opportunistic infection was 8 months (range from 41 days to 698 days) [see Warnings and Precautions (5.1)].

Malignancies

In the seven placebo-controlled trials in patients with RA, during the 0 month to 3 months exposure, malignancies excluding NMSC were reported in 0 patients who received placebo and 2 patients (0.3 events per 100 patient-years) who received either tofacitinib 5 mg or 10 mg twice daily.

The rate difference between treatment groups (and the corresponding 95% confidence interval) was 0.3 (-0.1, 0.7) events per 100 patient-years for the combined tofacitinib 5 mg and 10 mg twice daily group minus placebo.

In the seven placebo-controlled trials, during the 0 month to 12 months exposure, malignancies excluding NMSC were reported in 5 patients (0.4 events per 100 patient-years) who received tofacitinib 5 mg twice daily and 7 patients (0.6 events per 100 patient-years) who received tofacitinib 10 mg twice daily. The rate difference between tofacitinib doses (and the corresponding 95% confidence interval) was 0.2 (-0.4, 0.7) events per 100 patient-years for tofacitinib 10 mg twice daily minus tofacitinib 5 mg twice daily. One of these malignancies was a case of lymphoma that occurred during the 0- month to 12-month period in a patient treated with tofacitinib 10 mg twice daily. The most common types of malignancy, including malignancies observed during the long-term extension in tofacitinib -treated patients, were lung and breast cancer, followed by gastric, colorectal, renal cell, prostate cancer, lymphoma, and malignant melanoma [see Warnings and Precautions (5.3)].

Laboratory Abnormalities

Lymphopenia: In the placebo-controlled clinical trials in patients with RA, confirmed decreases in absolute lymphocyte counts below 500 cells/mm³ occurred in 0.04% of patients for the tofacitinib 5 mg twice daily and 10 mg twice daily groups combined during the first 3 months of exposure.

Confirmed lymphocyte counts less than 500 cells/mm³ were associated with an increased incidence of treated and serious infections [see Warnings and Precautions (5.8)].

Neutropenia: In the placebo-controlled clinical trials in patients with RA, confirmed decreases in ANC below 1,000 cells/mm³ occurred in 0.07% of patients for the tofacitinib 5 mg twice daily and 10 mg twice daily groups combined during the first 3 months of exposure.

There were no confirmed decreases in ANC below 500 cells/mm³ observed in any treatment group. There was no clear relationship between neutropenia and the occurrence of serious infections.

In the long-term safety population, the pattern and incidence of confirmed decreases in ANC remained consistent with what was seen in the placebo-controlled clinical trials [see Warnings and Precautions (5.8)].

Liver Enzyme Elevations: Confirmed increases in liver enzymes greater than 3 times the upper limit of normal (3x ULN) were observed in patients with RA treated with tofacitinib. In patients experiencing liver enzyme elevation, modification of treatment regimen, such as reduction in the dose of concomitant DMARD, interruption of tofacitinib, or reduction in tofacitinib dosage, resulted in decrease or normalization of liver enzymes.

In the placebo-controlled monotherapy trials (0 month to 3 months), no differences in the incidence of ALT or AST elevations were observed between the placebo, and tofacitinib 5 mg, and 10 mg twice daily groups.

In the placebo-controlled background DMARD trials (0 month to 3 months), ALT elevations greater than 3x ULN were observed in 1%, 1.3% and 1.2% of patients who received placebo, tofacitinib 5 mg, and 10 mg twice daily, respectively. In these trials, AST elevations greater than 3x ULN were observed in 0.6%, 0.5% and 0.4% of patients who received placebo, tofacitinib 5 mg, and 10 mg twice daily, respectively.

One case of drug-induced liver injury was reported in a patient treated with tofacitinib 10 mg twice daily for approximately 2.5 months. The patient developed symptomatic elevations of AST and ALT greater than 3x ULN and bilirubin elevations greater than 2x ULN, which required hospitalizations and a liver biopsy.

Lipid Elevations: In the placebo-controlled clinical trials in patients with RA, dose-related elevations in lipid parameters (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides) were observed at one month of exposure and remained stable thereafter. Changes in lipid parameters during the first 3 months of exposure in the placebo-controlled clinical trials are summarized below:

Mean LDL cholesterol increased by 15% in the tofacitinib 5 mg twice daily arm and 19% in the tofacitinib 10 mg twice daily arm. Mean HDL cholesterol increased by 10% in the tofacitinib 5 mg twice daily arm and 12% in the tofacitinib 10 mg twice daily arm. Mean LDL/HDL ratios were essentially unchanged in tofacitinib-treated patients. In a placebo-controlled clinical trial, elevations in LDL cholesterol and ApoB decreased to pretreatment levels in response to statin therapy.

In the long-term safety population, elevations in lipid parameters remained consistent with what was seen in the placebo-controlled clinical trials.

Serum Creatinine Elevations: In the placebo-controlled clinical trials in patients with RA, dose-related elevations in serum creatinine were observed with tofacitinib treatment. The mean increase in serum creatinine was < 0.1 mg/dL in the 12-month pooled safety analysis; however, with increasing duration of exposure in the long-term extensions, up to 2% of patients were discontinued from tofacitinib treatment due to the protocol-specified discontinuation criterion of an increase in creatinine by more than 50% of baseline. The clinical significance of the observed serum creatinine elevations is unknown.

Common Adverse Reactions

Table 5 displays adverse reactions that occurred in 2% or more of patients on tofacitinib 5 mg or 10 mg twice daily and at least 1% greater than in tofacitinib-treated patients that observed in placebo-treated patients with or without DMARD in the RA trials.

Preferred Term	Placebo	Tofacitinib 5 mg Twice Daily	Tofacitinib 10 mg Twice Daily**
Preferred Term	N = 809 (%)	N = 1,336 (%)	N = 1,349 (%)
Upper respiratory tract infection	3	4	4
Nasopharyngitis	3	4	3
Diarrhea	2	4	3
Headache	2	4	3
Hypertension	1	2	2

N reflects randomized and treated patients from the seven placebo-controlled clinical trials.

* reported in ≥ 2% of patients treated with either dose of tofacitinib and ≥ 1% greater than that reported for placebo.

** The recommended dose of tofacitinib for the treatment of RA is 5 mg twice daily [see Dosage and Administration (2)].

Other adverse reactions that occurred in placebo-controlled and open-label extension studies in patients with RA included:

Blood and lymphatic system disorders: Anemia

Infections and infestations: Diverticulitis

Metabolism and nutrition disorders: Dehydration

Psychiatric disorders: Insomnia

Nervous system disorders: Paresthesia

Respiratory, thoracic and mediastinal disorders: Dyspnea, cough, sinus congestion, interstitial lung disease (cases were limited to patients with RA and some were fatal)

Gastrointestinal disorders: Abdominal pain, dyspepsia, vomiting, gastritis, nausea

Hepatobiliary disorders: Hepatic steatosis

Skin and subcutaneous tissue disorders: Rash, erythema, pruritus

Musculoskeletal, connective tissue and bone disorders: Musculoskeletal pain, arthralgia, tendonitis, joint swelling

Neoplasms benign, malignant and unspecified (including cysts and polyps): Non-melanoma skin cancers

General disorders and administration site conditions: Pyrexia, fatigue, peripheral edema

Clinical Experience in Methotrexate-Naïve Patients

Study RA-VI was an active-controlled clinical trial in methotrexate-naïve patients [see Clinical Studies (14)]. The safety experience in these patients was consistent with Studies RA-I through V.

Adverse Reactions in Adults with Psoriatic Arthritis

The safety of tofacitinib was evaluated in 2 double-blind Phase 3 clinical trials in adults with active psoriatic arthritis (PsA):

Study PsA-I (NCT01877668) had a duration of 12 months and enrolled adults who had an inadequate response to a nonbiologic DMARD and who were naïve to treatment with a TNF blocker. Study PsA-I included a 3-month placebo-controlled period and also included adalimumab 40 mg subcutaneously once every 2 weeks for 12 months. Study PsA-II (NCT01882439) had a duration of 6 months and enrolled adults who had an inadequate response to at least one approved TNF blocker. This clinical trial included a 3-month placebo-controlled period. In these combined Phase 3 clinical trials, 238 patients were randomized and treated with tofacitinib 5 mg twice daily and 236 patients were randomized and treated with tofacitinib 10 mg twice daily. A dosage of tofacitinib 10 mg twice daily is not recommended for the treatment of PsA. For the treatment of adults with active PsA [see Indications and Usage (1.2)], the recommended dosage of tofacitinib is 5 mg twice daily [see Dosage and Administration (2.3)].

All patients in the clinical trials in patients with PsA were required to receive treatment with a stable dose of a nonbiologic DMARD [the majority (79%) received methotrexate]. The study population randomized and treated with tofacitinib (474 patients) included 45 (10%) patients aged 65 years or older and 66 (14%) patients with diabetes at baseline.

During the 2 PsA controlled clinical trials, there were:

3 malignancies (excluding NMSC) in 474 patients who received tofacitinib plus non-biologic DMARD (6 to 12 months exposure) 0 malignancies in 236 patients who received placebo plus non-biologic DMARD group (3 months exposure) and 0 malignancies in 106 patients in patients who received adalimumab plus non-biologic DMARD group (12 months exposure). No lymphomas were reported. Malignancies have also been observed in the long-term extension study in patients with PsA treated with tofacitinib.

The safety profile observed in adults with active PsA treated with tofacitinib was consistent with the safety profile observed in adults with RA.

Adverse Reactions in Adults with Ankylosing Spondylitis

The safety of tofacitinib was evaluated in adults with active ankylosing spondylitis (AS) in a double-blind placebo-controlled Phase 3 clinical trial (Study AS-I) and in a dose-ranging Phase 2 clinical trial (Study AS-II).

Study AS-I (NCT03502616) had a duration of 48 weeks and enrolled adults who had an inadequate response to at least 2 NSAIDs. Study AS-I included a 16-week double-blind period in which patients received tofacitinib 5 mg or placebo twice daily and a 32-week open-label treatment period in which all patients received tofacitinib 5 mg twice daily. Study AS-II (NCT01786668) had a duration of 16 weeks and enrolled adults who had an inadequate response to at least 2 NSAIDs. This clinical trial included a 12-week treatment period in which patients received either tofacitinib 2 mg (40% of the recommended dose), 5 mg, 10 mg, or placebo twice daily. A dosage of tofacitinib 10 mg twice daily is not recommended for the treatment of AS. For the treatment of adults with active AS [see Indications and Usage (1.3)], the recommended dosage of tofacitinib is 5 mg twice daily [see Dosage and Administration (2.3)]. In the combined Phase 2 and Phase 3 clinical trials, a total of 420 patients were treated with either tofacitinib 2 mg, 5 mg, or 10 mg twice daily. Of these, 316 patients were treated with tofacitinib 5 mg twice daily for up to 48 weeks. In the combined double-blind period, 185 patients were randomized to and treated with tofacitinib 5 mg twice daily and 187 to placebo for up to 16 weeks. Concomitant treatment with stable doses of nonbiologic DMARDs, NSAIDs, or corticosteroids (≤ 10 mg/day) was permitted. The study population randomized and treated with tofacitinib included 13 (3%) patients aged 65 years or older and 18 (4%) patients with diabetes at baseline.

The safety profile observed in adults with AS treated with tofacitinib was consistent with the safety profile observed in adults with RA and PsA.

Adverse Reactions in Pediatric Patients 2 Years of Age and Older with Polyarticular Course Juvenile Idiopathic Arthritis

Tofacitinib tablets and XELJANZ oral solution 5 mg twice daily or weight-based equivalent twice daily was studied in 225 pediatric patients from 2 years to 17 years of age in Study pcJIA-I [see Clinical Studies (14.4)] and one open-label extension study (Study A3921145). The total patient exposure (defined as patients who received at least one dose of tofacitinib tablets or XELJANZ oral solution) was 105.6 patient-years in Study pcJIA-I and 777.5 patient-years in Study A3921145.

In general, the types of adverse reactions in pediatric patients 2 years of age and older with pcJIA, were consistent with those seen in adults with RA and PsA (see Adverse Reactions in Adults with Rheumatoid Arthritis and Adverse Reactions in Adults with Psoriatic Arthritis).

Adverse Reactions in Adults with Ulcerative Colitis

The safety of tofacitinib has been evaluated in adults with moderately to severely active UC in 4 randomized, double-blind, placebo-controlled trials (UC-I, UC-II, UC-III, and dose-ranging UC-V) and an open-label long-term extension study (UC-IV) [see Clinical Studies (14.5)].

Adverse reactions reported in ≥ 5% of patients treated with either tofacitinib 5 mg or 10 mg twice daily and ≥ 1% greater than reported in patients receiving placebo in either the induction or maintenance clinical trials of patients with UC were: nasopharyngitis, elevated cholesterol levels, headache, upper respiratory tract infection, increased blood creatine phosphokinase, rash, diarrhea, and herpes zoster.

Induction Trials in Adults with UC

Common adverse reactions reported in ≥ 2% of patients treated with tofacitinib 10 mg twice daily and ≥ 1% greater in tofacitinib-treated patients than placebo-treated patients in the 3 induction trials of patients with UC (Studies UC-I, UC-II, and UC-V) were: headache, nasopharyngitis, elevated cholesterol levels, acne, increased blood creatine phosphokinase, and pyrexia.

Maintenance Trial in Adults with UC

Common adverse reactions reported in ≥ 4% of patients treated with either dosage of tofacitinib and ≥ 1% greater than reported in patients treated with placebo in the maintenance trial of patients with UC (Study UC-III) are shown in Table 6.

Preferred Term	Placebo	Tofacitinib 5 mg Twice Daily	Tofacitinib 10 mg Twice Daily
Preferred Term	N = 198 (%)	N = 198 (%)	N = 196 (%)
Nasopharyngitis	6	10	14
Elevated cholesterol levels**	1	5	9
Headache	6	9	3
Upper respiratory tract infection	4	7	6
Increased blood creatine phosphokinase	2	3	7
Rash	4	3	6
Diarrhea	3	2	5
Herpes zoster	1	1	5
Gastroenteritis	3	3	4
Anemia	2	4	2
Nausea	3	1	4

* Reported in ≥ 4% of patients treated with either tofacitinib dosage and ≥ 1% greater in tofacitinib-treated patients than placebo-treated patients.

** Includes hypercholesterolemia, hyperlipidemia, blood cholesterol increased, dyslipidemia, blood triglycerides increased, low-density lipoprotein increased, low-density lipoprotein abnormal, or lipids increased.

Dose-dependent adverse reactions seen in patients treated with tofacitinib 10 mg twice daily, in comparison to 5 mg twice daily, include the following: herpes zoster infections, serious infections, and NMSC [see Warnings and Precautions (5.1, 5.3)].

During the UC controlled clinical studies (8-week induction and 52-week maintenance studies), which included 1,220 patients, 0 cases of solid cancer or lymphoma were observed in tofacitinib-treated patients.

In the long-term extension study, malignancies (including solid cancers, lymphomas and NMSC) were observed in patients treated with tofacitinib 5 mg and 10 mg twice daily [see Warnings and Precautions (5.3)]. Five cases of pulmonary embolism were reported in patients taking tofacitinib 10 mg twice daily, including one fatality in a patient with advanced cancer [see Warnings and Precautions (5.5)].

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of tofacitinib tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune system disorders: Drug hypersensitivity (events such as angioedema and urticaria have been observed)

Skin and subcutaneous tissue disorders: Acne

7 DRUG INTERACTIONS

Table 7 includes drugs with clinically significant drug interactions when concomitantly used with tofacitinib tablets and instructions for preventing or managing them.

Strong CYP3A4 Inhibitors (e.g., ketoconazole)
Clinical Impact	Increased exposure to tofacitinib
Intervention	Dosage modification of tofacitinib tablets is recommended [see Dosage and Administration (2), Clinical Pharmacology, Figure 3 (12.3)]
Moderate CYP3A4 Inhibitors Concomitantly Used with Strong CYP2C19 Inhibitors (e.g., fluconazole)
Clinical Impact	Increased exposure to tofacitinib
Intervention	Dosage modification of tofacitinib tablets is recommended [see Dosage and Administration (2), Clinical Pharmacology, Figure 3 (12.3)]
Strong CYP3A4 Inducers (e.g., rifampin)
Clinical Impact	Decreased exposure to tofacitinib and may result in loss of or reduced clinical response
Intervention	Concomitant use with tofacitinib tablets is not recommended [see Clinical Pharmacology, Figure 3 (12.3)]
Immunosuppressive Drugs (e.g., azathioprine, tacrolimus, cyclosporine)
Clinical Impact	Risk of added immunosuppression; concomitant use of tofacitinib tablets with biologic DMARDs or potent immunosuppressants has not been studied in patients with RA, PsA, AS, UC, or pcJIA.
Intervention	Concomitant use with tofacitinib tablets is not recommended [see Indications and Usage (1), Clinical Pharmacology, Figure 3 (12.3)]

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

The available data with tofacitinib tablets from a pregnancy exposure registry that enrolled 11 exposed pregnant females, pharmacovigilance, and published literature are insufficient to draw conclusions about a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are risks to the mother and the fetus associated with RA and UC in pregnancy (see Clinical Considerations). In animal reproduction studies, fetocidal and teratogenic effects were noted when pregnant rats and rabbits received tofacitinib during the period of organogenesis at exposures multiples of 73-times and 6.3-times the maximum recommended dose of 10 mg twice daily, respectively. Further, in a peri- and post-natal study in rats, tofacitinib resulted in reductions in live litter size, postnatal survival, and pup body weights at exposure multiples of approximately 73-times the recommended dosage of 5 mg twice daily and approximately 36 times the maximum recommended dosage of 10 mg twice daily, respectively (see Data).

The background risks of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risks in the U.S. general population of major birth defects and miscarriages are 2% to 4% and 15% to 20% of clinically recognized pregnancies, respectively.

Clinical Considerations

Disease-Associated Maternal and/or Embryo/Fetal Risk: Published data suggest that increased disease activity is associated with the risk of developing adverse pregnancy outcomes in women with RA or UC. Adverse pregnancy outcomes include preterm delivery (before 37 weeks of gestation), low birth weight (less than 2500 grams) infants, and small for gestational age at birth.

Data

Animal Data: In a rat embryofetal developmental study, in which pregnant rats received tofacitinib during organogenesis, tofacitinib was teratogenic at exposure levels approximately 146 times the recommended dose of 5 mg twice daily, and approximately 73 times the maximum recommended dose of 10 mg twice daily (on an AUC basis at oral doses of 100 mg/kg/day in rats). Teratogenic effects consisted of external and soft tissue malformations of anasarca and membranous ventricular septal defects, respectively; and skeletal malformations or variations (absent cervical arch; bent femur, fibula, humerus, radius, scapula, tibia, and ulna; sternoschisis; absent rib; misshapen femur; branched rib; fused rib; fused sternebra; and hemicentric thoracic centrum). In addition, there was an increase in post-implantation loss, consisting of early and late resorptions, resulting in a reduced number of viable fetuses. Mean fetal body weight was reduced. No developmental toxicity was observed in rats at exposure levels approximately 58 times the recommended dose of 5 mg twice daily, and approximately 29 times the maximum recommended dose of 10 mg twice daily (on an AUC basis at oral doses of 30 mg/kg/day in pregnant rats).

In a rabbit embryofetal developmental study in which pregnant rabbits received tofacitinib during the period of organogenesis, tofacitinib was teratogenic at exposure levels approximately 13 times the recommended dose of 5 mg twice daily, and approximately 6.3 times the maximum recommended dose of 10 mg twice daily (on an AUC basis at oral doses of 30 mg/kg/day in rabbits) in the absence of signs of maternal toxicity. Teratogenic effects included thoracogastroschisis, omphalocele, membranous ventricular septal defects, and cranial/skeletal malformations (microstomia, microphthalmia), mid-line and tail defects. In addition, there was an increase in post-implantation loss associated with late resorptions. No developmental toxicity was observed in rabbits at exposure levels approximately 3 times the recommended dose of 5 mg twice daily, and approximately 1.5 times the maximum recommended dose of 10 mg twice daily (on an AUC basis at oral doses of 10 mg/kg/day in pregnant rabbits).

In a peri- and postnatal development study in pregnant rats that received tofacitinib from gestation day 6 through day 20 of lactation, there were reductions in live litter size, postnatal survival, and pup body weights at exposure levels approximately 73 times the recommended dose of 5 mg twice daily, and approximately 36 times the maximum recommended dose of 10 mg twice daily (on an AUC basis at oral doses of 50 mg/kg/day in rats). There was no effect on behavioral and learning assessments, sexual maturation or the ability of the F1 generation rats to mate and produce viable F2 generation fetuses in rats at exposure levels approximately 17 times the recommended dose of 5 mg twice daily, and approximately 8.3 times the maximum recommended dose of 10 mg twice daily (on an AUC basis at oral doses of 10 mg/kg/day in rats).

8.2 Lactation

Risk Summary

Based on published data, tofacitinib is present in human milk. Data on the effects of tofacitinib on the breastfed infant is limited to a small number of cases with no reported adverse effects. There are no data on the effects on milk production. Given the serious adverse reactions seen in patients treated with tofacitinib tablets, such as increased risk of serious infections, advise patients that breastfeeding is not recommended during treatment and for at least 18 hours after the last dose of tofacitinib tablets (approximately 6 elimination half-lives).

Data

Following administration of tofacitinib to lactating rats, concentrations of tofacitinib in milk over time paralleled those in serum and were approximately 2 times higher in milk relative to maternal serum at all time points measured.

8.3 Females and Males of Reproductive Potential

Contraception

Females

In an animal reproduction study, tofacitinib at AUC multiples of 13 times the recommended dosage of 5 mg twice daily and 6.3 times the maximum recommended dosage of 10 mg twice daily demonstrated adverse embryo-fetal findings [see Use in Specific Populations (8.1)].

However, there is uncertainty as to how these animal findings relate to females of reproductive potential treated with the recommended clinical dosage. Consider pregnancy planning and prevention for females of reproductive potential.

Infertility

Females

Based on findings in rats, treatment with tofacitinib tablets may result in reduced fertility in females of reproductive potential. It is not known if this effect is reversible [see Nonclinical Toxicology (13.1)].

8.4 Pediatric Use

The safety and effectiveness of tofacitinib tablets in pediatric patients for indications, other than in patients with active pcJIA and PsA, have not been established.

The safety and effectiveness of tofacitinib tablets have not been established in pediatric patients less than 2 years of age.

Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA)

The safety and effectiveness of tofacitinib tablets for the treatment of active pcJIA have been established in pediatric patients 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers.

Use of tofacitinib tablets for this indication is supported by evidence from adequate and well-controlled studies of tofacitinib tablets in adults with RA, pharmacokinetic (PK) data from adult patients with RA, and with additional safety, efficacy, and PK data from a clinical trial of tofacitinib in pediatric patients 2 years and older with active pcJIA (Study pcJIA-I) [see Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14.1, 14.4)].

Adverse reactions observed in pediatric patients with pcJIA who received tofacitinib were consistent with those reported in adults with RA [see Adverse Reactions (6.1)].

Psoriatic Arthritis

The safety and effectiveness of tofacitinib tablets for the treatment of active PsA have been established in pediatric patients 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers.

Use of tofacitinib for this indication is supported by evidence from well-controlled studies of tofacitinib tablets in adults with PsA, PK data from adults with PsA, and PK data from a clinical trial of tofacitinib in 225 pediatric patients with JIA, and safety data from 280 pediatric patients 2 years of age and older with JIA [see Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14.2)]. Following administration of the recommended tofacitinib dosage in pediatric patients 2 years of age and older with PsA, tofacitinib plasma exposures are predicted to be comparable to those observed in adults with PsA based on population PK modeling and simulation [see Clinical Pharmacology (12.3)].

Systemic Juvenile Idiopathic Arthritis

The safety and effectiveness of tofacitinib for the treatment of pediatric patients with systemic juvenile idiopathic arthritis (sJIA) have not been established.

Additional pediatric information describing a clinical study in which efficacy was not demonstrated is approved for Pfizer Inc.'s Xeljanz (tofacitinib) tablets.

However, due to Pfizer Inc.'s marketing exclusivity rights, this drug product is not labelled with that information.

8.5 Geriatric Use

Of the 3,315 adults who were enrolled in clinical trials with RA (Studies RA-I to V), a total of 505 patients were 65 years of age and older, including 71 patients 75 years and older. The frequency of serious infection among tofacitinib tablets-treated patients 65 years of age and older was higher than among those adults under the age of 65.

Of the 1,156 tofacitinib tablet-treated patients in clinical trials of patients with UC, a total of 77 patients (7%) were 65 years of age or older. Clinical studies of tofacitinib in patients with UC did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger adult patients.

Of the 783 tofacitinib tablet-treated patients in clinical trials of patients with PsA, a total of 72 (9.2%) patients were 65 years of age and older, including 2 (0.3%) patients 75 years and older. These clinical studies did not include sufficient numbers of patients aged 65 years and older with PsA to determine if they respond differently from younger adult patients.

Of the 420 tofacitinib tablet-treated patients in clinical trials of patients with AS, a total of 12 (2.9%) patients were 65 years of age and older, including 1 (0.2%) patient 75 years and older. These clinical studies did not include sufficient numbers of patients aged 65 years and older with AS to determine if they respond differently from younger adult patients.

8.6 Renal Impairment

Moderate and Severe Renal Impairment

Tofacitinib-treated patients with moderate renal impairment (RI) (CLcr ≥ 30 and ≤ 50 mL/minute) or severe RI (< 30 mL/minute) had greater tofacitinib blood concentrations than tofacitinib-treated patients with normal renal function (CLcr > 80 mL/minute). The recommended dosage of tofacitinib tablets in patients with moderate or severe RI (including those with severe RI who are undergoing hemodialysis) is lower than the recommended dosage in patients with normal renal function [see Dosage and Administration (2.3, 2.4, 2.5)].

Mild Renal Impairment

The recommended dosage in patients with mild RI (CLcr > 50 and ≤ 80 mL/minute) is the same as patients with normal renal function.

8.7 Hepatic Impairment

Severe Hepatic Impairment

Tofacitinib tablets has not been studied in patients with severe hepatic impairment (HI) (Child-Pugh C); therefore, use of tofacitinib tablets in patients with severe HI is not recommended.

Moderate Hepatic Impairment

Tofacitinib-treated patients with moderate hepatic impairment (Child-Pugh B) had greater tofacitinib blood concentration than tofacitinib-treated patients with normal hepatic function [see Clinical Pharmacology (12.3)]. Higher blood concentrations may increase the risk of some adverse reactions. The recommended tofacitinib tablets dosage in patients with moderate HI is lower than the recommended dosage in patients with normal hepatic function [see Dosage and Administration (2.3, 2.4, 2.5)].

Mild Hepatic Impairment

The recommended dosage of tofacitinib tablets in patients with mild hepatic impairment (Child-Pugh A) is the same as patients with normal hepatic function.

Hepatitis B or C Serology

The safety and efficacy of tofacitinib tablets have not been studied in patients with positive hepatitis B virus or hepatitis C virus serology.

10 OVERDOSAGE

There is no specific antidote for overdose with tofacitinib tablets. In case of an overdose, it is recommended that the patient be monitored for signs and symptoms of adverse reactions.

In a study in patients with end-stage renal disease (ESRD) undergoing hemodialysis, plasma tofacitinib concentrations declined more rapidly during the period of hemodialysis and dialyzer efficiency, calculated as dialyzer clearance/blood flow entering the dialyzer, was high [mean (SD) = 0.73 (0.15)]. However, due to the significant non-renal clearance of tofacitinib, the fraction of total elimination occurring by hemodialysis was small, and thus, limits the value of hemodialysis for treatment of overdose with tofacitinib tablets.

Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.

11 DESCRIPTION

Tofacitinib tablets are formulated with the citrate salt of tofacitinib, a JAK inhibitor.

Tofacitinib citrate is a white to off-white powder and soluble in dimethylsulfoxide and

insoluble in water with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7Hpyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-piperidinepropanenitrile, 2-hydroxy-1,2,3- propanetricarboxylate (1:1).

The solubility of tofacitinib citrate in water is 2.9 mg/mL.

Tofacitinib citrate has a molecular weight of 504.5 Daltons (or 312.4 Daltons as the

tofacitinib free base) and a molecular formula of C₁₆H₂₀N₆O•C₆H₈O₇. The chemical

structure of tofacitinib citrate is:

Each 5 mg and 10 mg film-coated tablet contains tofacitinib equivalent to 8.08 mg and 16.15 mg of tofacitinib citrate respectively for oral administration and contains following inactive ingredients: croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone and titanium dioxide.

Additionally, each 10 mg tablet contains FD&C blue #1 Aluminum Lake and iron oxide yellow.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Tofacitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Tofacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signaling through pairing of JAKs (e.g., JAK1/JAK3, JAK1/JAK2, JAK1/TyK2, JAK2/JAK2). Tofacitinib inhibited the in vitro activities of JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 combinations with IC₅₀ of 406, 56, and 1377 nM, respectively. However, the relevance of specific JAK combinations to therapeutic effectiveness is not known.

12.2 Pharmacodynamics

Treatment with tofacitinib was associated with dose-dependent reductions of circulating CD16/56+ natural killer cells, with estimated maximum reductions occurring at approximately 8 weeks to 10 weeks after initiation of therapy. These changes generally resolved within 2 weeks to 6 weeks after discontinuation of treatment. Treatment with tofacitinib was associated with dose-dependent increases in B cell counts. Changes in circulating T-lymphocyte counts and T-lymphocyte subsets (CD3+, CD4+ and CD8+) were small and inconsistent. The clinical significance of these changes is unknown.

Total serum IgG, IgM, and IgA levels after 6-month dosing in patients with rheumatoid arthritis (RA) were lower than in patients who received placebo; however, changes were small and not dose-dependent.

After treatment with tofacitinib in patients with RA, rapid decreases in serum C-reactive protein (CRP) were observed and maintained throughout dosing. Changes in CRP observed with tofacitinib treatment do not reverse fully within 2 weeks after discontinuation, indicating a longer duration of pharmacodynamic activity compared to the pharmacokinetic half-life.

Similar changes in T cells, B cells, and serum CRP have been observed in patients with active psoriatic arthritis (PsA) although reversibility was not assessed. Total serum immunoglobulins were not assessed in patients with active PsA.

12.3 Pharmacokinetics

Following oral administration of tofacitinib tablets, peak plasma concentrations were reached within 0.5 hour to 1 hour, elimination half-life was about 3 hours and a dose-proportional increase in systemic exposure was observed in the therapeutic dosage range. Steady state concentrations were achieved in 24 hours to 48 hours with negligible accumulation after twice daily administration.

Table 8 describes the pharmacokinetic parameters of tofacitinib tablets.

PK Parameters^a (CV%)	Tofacitinib Tablets
Dosing Regimen	5 mg Twice Daily	10 mg Twice Daily
AUC₂₄ (ng.hr/mL)	263.4 (15)	539.6 (22)
C_max (ng/mL)	42.7 (26)	84.7 (18)
C_min (ng/mL)	1.41 (40)	3.10 (54)
T_max (hours)	1 (0.5 to 14^b)	0.8 (0.5 to 14^b)

Abbreviations: AUC₂₄ = area under the concentration time profile from time 0 to 24 hours; C_max = maximum plasma concentration; C_min = minimum plasma concentration; T_max = time to C_max; CV = Coefficient of variation.

a Values represent the geometric mean, except T_max, for which is the median (range) is shown.

^b Values beyond 12 hours were after the evening dose which was administered 12 hours after the morning dose of twice-daily tofacitinib tablets.

Absorption

Tofacitinib tablets

The absolute oral bioavailability of tofacitinib is 74%. Coadministration of tofacitinib with a high-fat meal resulted in no changes in AUC while C_max was reduced by 32%. In clinical trials, tofacitinib was administered without regard to meals [see Dosage and Administration (2.2)].

Distribution

After intravenous administration, the volume of distribution was 87 L. The protein binding of tofacitinib is approximately 40%. Tofacitinib binds predominantly to albumin and does not appear to bind to α1-acid glycoprotein. Tofacitinib distributes equally between red blood cells and plasma.

Metabolism and Excretion

Clearance mechanisms for tofacitinib are approximately 70% hepatic metabolism and 30% renal excretion of the parent drug. The metabolism of tofacitinib is primarily mediated by CYP3A4 with minor contribution from CYP2C19. In a human radiolabeled study, more than 65% of the total circulating radioactivity was accounted for by unchanged tofacitinib, with the remaining 35% attributed to 8 metabolites, each accounting for less than 8% of total radioactivity. The pharmacologic activity of tofacitinib is attributed to the parent molecule.

Pharmacokinetics in Patients with RA, PsA, AS, and UC

Population pharmacokinetic (PK) analyses indicated that PK characteristics were similar between patients with RA, PsA, ankylosing spondylitis, and UC. The coefficient of variation (%) in AUC of tofacitinib were generally similar across different disease patients, ranging from 22% to 34% (Table 9).

Pharmacokinetic Parameters^a Geometric Mean (CV%)	Tofacitinib Tablets 5 mg Twice Daily				Tofacitinib Tablets 10 mg Twice Daily
Pharmacokinetic Parameters^a Geometric Mean (CV%)	Rheumatoid Arthritis	Psoriatic Arthritis	Ankylosing Spondylitis	Ulcerative Colitis	Ulcerative Colitis
AUC_0-24,ss (ngꞏh/mL)	504 (22%)	419 (34.1%)	381 (25.4%)	423 (22.6%)	807 (24.6%)

Abbreviations: AUC_0-24,ss = area under the plasma concentration-time curve over 24 hours at steady state; CV = coefficient of variation.

^a Pharmacokinetic parameters estimated based on population pharmacokinetic analysis.

Specific Populations

Covariate evaluation as part of population PK analyses in adult patient populations indicated no clinically relevant change in tofacitinib exposure, after accounting for differences in renal function (i.e., creatinine clearance) between patients, based on age, weight, biological sex and race (Figure 1). An approximately linear relationship between body weight and volume of distribution was observed, resulting in higher peak (C_max) and lower trough (C_min) concentrations in lighter patients. However, this difference is not considered to be clinically relevant.

Covariate evaluation as part of population PK analyses in pediatric patients with pcJIA, including PsA, identified body weight significantly impacting tofacitinib exposure, which supports weight-based dosing in this population. There were no identified clinically significant differences in tofacitinib exposure with different age, biological sex, racial, or pcJIA or PsA disease severity groups.

The effect of renal and hepatic impairment and other intrinsic factors on the PK of tofacitinib is shown in Figure 1.

Figure 1: Impact of Intrinsic Factors on Tofacitinib Pharmacokinetics

Note: Reference values for weight, age, biological sex, and race comparisons are 70 kg, 55 years, male, and white, respectively; reference groups for renal and hepatic impairment data are patients with normal renal and hepatic function. Renal function was estimated using creatinine clearance by Cockcroft-Gault method and hepatic function was estimated using Child-Pugh scoring method.

In patients with end-stage renal disease maintained on hemodialysis, mean AUC was approximately 40% higher compared with historical healthy subject data, consistent with approximately 30% contribution of renal clearance to the total clearance of tofacitinib [see Dosage and Administration (2.3, 2.4, 2.5) and Use in Specific Populations (8.6)].

Drug Interaction Studies

Potential for Tofacitinib Tablets to Influence the PK of Other Drugs

In vitro studies indicate that tofacitinib does not significantly inhibit or induce the activity of the major human drug-metabolizing CYPs (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) at concentrations corresponding to the steady state C_max of a 10 mg twice daily dose. These in vitro results were confirmed by a human drug interaction study showing no changes in the pharmacokinetics of midazolam, a highly sensitive CYP3A4 substrate, when concomitantly administered with tofacitinib.

In vitro studies indicate that tofacitinib does not significantly inhibit the activity of the major human drug-metabolizing uridine 5'-diphospho-glucuronosyltransferases (UGTs) [UGT1A1, UGT1A4, UGT1A6, UGT1A9, and UGT2B7] at concentrations exceeding 250 times the steady state C_max of a 10 mg twice daily dose.

In patients with RA, the oral clearance of tofacitinib does not vary with time, indicating that tofacitinib does not normalize CYP enzyme activity in patients with RA. Therefore, concomitant use with tofacitinib tablets is not expected to result in clinically relevant increases in the metabolism of CYP substrates in patients with RA.

In vitro data indicate that the potential for tofacitinib to inhibit transporters such as

P-glycoprotein, organic anionic or cationic transporters at therapeutic concentrations is low.

The impact of tofacitinib on the PK of other drugs for the concomitant drugs are shown in Figure 2.

Figure 2: Impact of Tofacitinib on the Pharmacokinetics of Other Drugs

Note: Reference group is administration of concomitant medication alone; OCT = Organic Cationic Transporter; MATE = Multidrug and Toxic Compound Extrusion.

Potential for Other Drugs to Influence the Pharmacokinetics of Tofacitinib

Since tofacitinib is metabolized by CYP3A4, interaction with drugs that inhibit or induce CYP3A4 is likely. Inhibitors of CYP2C19 alone or P-glycoprotein are unlikely to substantially alter the pharmacokinetics of tofacitinib (see Figure 3).

Figure 3: Impact of Other Drugs on the Pharmacokinetics of Tofacitinib

Note: Reference group is administration of tofacitinib alone.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

In a 39-week toxicology study in monkeys, tofacitinib at exposure levels approximately 6 times the recommended dose of 5 mg twice daily, and approximately 3 times the 10 mg twice daily dose (on an AUC basis at oral doses of 5 mg/kg twice daily) produced lymphomas. No lymphomas were observed in this study at exposure levels 1 times the recommended dose of 5 mg twice daily, and approximately 0.5 times the 10 mg twice daily dose (on an AUC basis at oral doses of 1 mg/kg twice daily).

The carcinogenic potential of tofacitinib was assessed in 6-month rasH2 transgenic mouse carcinogenicity and 2-year rat carcinogenicity studies. Tofacitinib, at exposure levels approximately 34 times the recommended dose of 5 mg twice daily, and approximately 17 times the 10 mg twice daily dose (on an AUC basis at oral doses of 200 mg/kg/day) was not carcinogenic in mice.

In the 24-month oral carcinogenicity study in Sprague-Dawley rats, tofacitinib caused benign Leydig cell tumors, hibernomas (malignancy of brown adipose tissue), and benign thymomas at doses greater than or equal to 30 mg/kg/day (approximately 42 times the exposure levels at the recommended dose of 5 mg twice daily, and approximately 21 times the 10 mg twice daily dose on an AUC basis). The relevance of benign Leydig cell tumors to human risk is not known.

Tofacitinib was not mutagenic in the bacterial reverse mutation assay. It was positive for clastogenicity in the in vitro chromosome aberration assay with human lymphocytes in the presence of metabolic enzymes, but negative in the absence of metabolic enzymes. Tofacitinib was negative in the in vivo rat micronucleus assay and in the in vitro CHO-HGPRT assay and the in vivo rat hepatocyte unscheduled DNA synthesis assay.

In rats, tofacitinib at exposure levels approximately 17 times the recommended dose of 5 mg twice daily, and approximately 8.3 times the 10 mg twice daily dose (on an AUC basis at oral doses of 10 mg/kg/day) reduced female fertility due to increased post-implantation loss. There was no impairment of female rat fertility at exposure levels of tofacitinib equal to the recommended dose of 5 mg twice daily, and approximately 0.5 times the 10 mg twice daily dose (on an AUC basis at oral doses of 1 mg/kg/day). Tofacitinib exposure levels at approximately 133 times the recommended dose of 5 mg twice daily, and approximately 67 times the 10 mg twice daily dose (on an AUC basis at oral doses of 100 mg/kg/day) had no effect on male fertility, sperm motility, or sperm concentration.

14 CLINICAL STUDIES

14.1 Clinical Studies in Rheumatoid Arthritis

The rheumatoid arthritis (RA) clinical development program with tofacitinib tablets (referred to as "tofacitinib" in this subsection of labeling) included six randomized controlled trials in adults with moderate to severe active RA.

Trial Design

Study RA-I (NCT00814307) was a 6-month monotherapy trial in which 610 patients with moderate to severe active RA who had an inadequate response to a DMARD (nonbiologic or biologic) received tofacitinib 5 mg or 10 mg twice daily or placebo added to their background DMARD. At the Month 3 visit, all patients randomized to placebo treatment were switched in a blinded fashion to a second predetermined treatment of tofacitinib 5 mg or 10 mg twice daily. The primary endpoints at Month 3 were the proportion of patients who achieved an ACR20 response, changes in Health Assessment Questionnaire – Disability Index (HAQ-DI), and rates of Disease Activity Score DAS28-4(ESR) less than 2.6. Study RA-II (NCT00856544) was a 12-month trial in which 792 patients with moderate to severe active RA who had an inadequate response to a nonbiologic DMARD received tofacitinib 5 mg or 10 mg twice daily or placebo added to background DMARD treatment (excluding potent immunosuppressive treatments such as azathioprine or cyclosporine). At the Month 3 visit, nonresponding patients were switched in a blinded fashion to a second predetermined treatment of tofacitinib 5 mg or 10 mg twice daily. At the end of Month 6, all patients treated with placebo were switched to their second predetermined tofacitinib treatment in a blinded fashion. The primary endpoints were the proportion of patients who achieved an ACR20 response at Month 6, changes in HAQ-DI at Month 3, and rates of DAS28-4(ESR) less than 2.6 at Month 6. Study RA-III (NCT00853385) was a 12-month trial in 717 patients with moderate to severe active RA who had an inadequate response to methotrexate (MTX). Patients received tofacitinib 5 mg or 10 mg orally twice daily, adalimumab 40 mg subcutaneously every other week, or placebo added to background MTX. Patients treated with placebo were switched as in Study RA-II. The primary endpoints were the proportion of patients who achieved an ACR20 response at Month 6, HAQ-DI at Month 3, and DAS28-4(ESR) less than 2.6 at Month 6. Study RA-IV (NCT00847613) was a 2-year trial with a planned analysis at 1 year in which 797 patients with moderate to severe active RA who had an inadequate response to MTX received tofacitinib 5 mg or 10 mg twice daily or placebo added to background MTX. Patients treated with placebo were switched as in Study RA-II. The primary endpoints were the proportion of patients who achieved an ACR20 response at Month 6, mean change from baseline in van der Heijde-modified total Sharp Score (mTSS) at Month 6, HAQ-DI at Month 3, and DAS28-4(ESR) less than 2.6 at Month 6. Study RA-V (NCT00960440) was a 6-month trial in which 399 patients with moderate to severe active RA who had an inadequate response to at least one approved TNF blocking biological product received tofacitinib 5 mg or 10 mg twice daily or placebo added to background MTX. At the Month 3 visit, all patients randomized to placebo treatment were switched in a blinded fashion to a second predetermined treatment of tofacitinib 5 or 10 mg twice daily. The primary endpoints at Month 3 were the proportion of patients who achieved an ACR20 response, HAQ-DI, and DAS28-4(ESR) less than 2.6. Study RA-VI (NCT01039688) was a 2-year monotherapy trial with a planned analysis at 1 year in which 952 MTX-naïve patients with moderate to severe active RA received tofacitinib 5 or 10 mg twice daily or MTX dose-titrated over 8 weeks to 20 mg weekly. The primary endpoints were mean change from baseline in van der Heijde-modified Total Sharp Score (mTSS) at Month 6 and the proportion of patients who achieved an ACR70 response at Month 6. Although other dosages have been studied, the recommended dosage of tofacitinib is 5 mg twice daily. Tofacitinib 10 mg twice daily is not recommended for the treatment of RA [see Dosage and Administration (2.3)].

Clinical Response

The percentages of tofacitinib-treated patients who achieved ACR20, ACR50, and ACR70 responses in Studies RA-I, IV, and V are shown in Table 10. Similar results were observed with Studies RA-II and III. In trials RA-I through V, patients treated with 5 mg twice daily tofacitinib had higher ACR20, ACR50, and ACR70 response rates versus patients treated with placebo, with or without background DMARD treatment, at Month 3 and Month 6. Higher ACR20 response rates were observed within 2 weeks compared to placebo. In the 12-month trials, ACR response rates in tofacitinib-treated patients were consistent at 6 and 12 months.

^a N is number of randomized and treated patients.
^bNA (not applicable), as data for placebo treatment is not available beyond 3 months in Studies RA-I and RA-V due to placebo advancement.
^cInadequate response to at least one DMARD (biologic or nonbiologic) due to lack of efficacy or toxicity.
^dInadequate response to MTX defined as the presence of sufficient residual disease activity to meet the entry criteria.
^eInadequate response to a least one TNF blocker due to lack of efficacy and/or intolerance.
	Monotherapy in Nonbiologic or Biologic DMARD Inadequate Responders^c		MTX Inadequate Responders^d		TNF Blocker Inadequate Responders^e
	Study RA-I		Study RA-IV		Study RA-V
N^a	Placebo + background DMARD	Tofacitinib 5 mg Twice Daily + background DMARD	Placebo + background MTX	Tofacitinib 5 mg Twice Daily + background MTX	Placebo + background MTX	Tofacitinib 5 mg Twice Daily + background MTX
	122	243	160	321	132	133
ACR20
Month 3	26%	59%	27%	55%	24%	41%
Month 6	NA^b	69%	25%	50%	NA	51%
ACR50
Month 3	12%	31%	8%	29%	8%	26%
Month 6	NA	42%	9%	32%	NA	37%
ACR70
Month 3	6%	15%	3%	11%	2%	14%
Month 6	NA	22%	1%	14%	NA	16%

In Study RA-IV, a greater proportion of patients treated with tofacitinib 5 mg twice daily plus MTX achieved a low level of disease activity as measured by a DAS28-4(ESR) less than 2.6 at 6 months compared to those treated with MTX alone (Table 11).

	Study RA-IV
DAS28-4(ESR) Less Than 2.6	Placebo + MTX 160	Tofacitinib 5 mg Twice Daily + MTX 321
Proportion of responders at Month 6 (n)	1% (2)	6% (19)
Of responders, proportion with 0 active joints (n)	50% (1)	42% (8)
Of responders, proportion with 1 active joint (n)	0	5% (1)
Of responders, proportion with 2 active joints (n)	0	32% (6)
Of responders, proportion with 3 or more active joints (n)	50% (1)	21% (4)

The results of the components of the ACR response criteria for Study RA-IV are shown in Table 12. Similar results were observed for tofacitinib in Studies RA-I, II, III, V, and VI.

	Study RA-IV
	Placebo + MTX N=160		Tofacitinib 5 mg Twice Daily + MTX N=321
Component (mean)^a	Baseline	Month 3^a	Baseline	Month 3^a
Number of tender	23	18	24	13
joints	(13)	(14)	(14)	(14)
(0-68)
Number of swollen	14	10	14	6
joints	(9)	(9)	(8)	(8)
(0-66)
Pain^b	55	47	58	34
Pain^b	(24)	(24)	(23)	(23)
Patient global	54	47	58	35
assessment^b	(23)	(24)	(24)	(23)
Disability index	1.32	1.19	1.41	0.99
(HAQ-DI)^c	(0.67)	(0.68)	(0.68)	(0.65)
Physician global	56	43	59	30
assessment^b	(18)	(22)	(16)	(19)
CRP (mg/L)	13.7	14.6	15.3	7.1
	(14.9)	(18.7)	(19)	(19.1)

^a Data shown is mean (Standard Deviation) at Month 3.

^b Visual analog scale: 0 = best, 100 = worst.

^c Health Assessment Questionnaire Disability Index: 0 = best, 3 = worst; 20 questions; categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities.

The percent of ACR20 responders by visit for Study RA-IV is shown in Figure 4. Similar responses were observed for tofacitinib in Studies RA-I, II, III, V, and VI.

Figure 4: Percentage of ACR20 Responders by Visit Through Month 6 in Study RA-IV

Radiographic Response

Two studies were conducted to evaluate the effect of tofacitinib on structural joint damage. In Study RA-IV and Study RA-VI, progression of structural joint damage was assessed radiographically and expressed as change from baseline in mTSS and its components, the erosion score and joint space narrowing score, at Months 6 and 12. The proportion of patients with no radiographic progression (mTSS change less than or equal to 0) was also assessed.

In Study RA-IV, tofacitinib 5 mg twice daily reduced the mean progression of structural damage (not statistically significant) as shown in Table 13. Analyses of erosion and joint space narrowing scores were consistent with the overall results.

In the placebo plus MTX group, 74% of patients experienced no radiographic progression at Month 6 compared to 84% of patients treated with tofacitinib plus MTX 5 mg twice daily.

In Study RA-VI, tofacitinib monotherapy inhibited the progression of structural damage compared to MTX at Months 6 and 12 as shown in Table 13. Analyses of erosion and joint space narrowing scores were consistent with the overall results.

In the MTX group, 55% of patients experienced no radiographic progression at Month 6 compared to 73% of patients treated with tofacitinib 5 mg twice daily.

	Study RA-IV
	Placebo N=139 Mean (SD)^a	Tofacitinib 5 mg Twice Daily N=277 Mean (SD)^a	Tofacitinib 5 mg Twice Daily Mean Difference from Placebo^b (CI)
mTSS^c Baseline Month 6	33 (42) 0.5 (2)	31 (48) 0.1 (1.7)	- -0.3 (-0.7, 0)
	Study RA-VI
	MTX N=166 Mean (SD)^a	Tofacitinib 5 mg Twice Daily N=346 Mean (SD) ^a	Tofacitinib 5 mg Twice Daily Mean Difference from MTX^b (CI)
mTSS^c Baseline Month 6 Month 12	17 (29) 0.8 (2.7) 1.3 (3.7)	20 (40) 0.2 (2.3) 0.4 (3)	- -0.7 (-1, -0.3) -0.9 (-1.4, -0.4)

^a SD = Standard Deviation

^b Difference between least squares means tofacitinib minus placebo or MTX (95% CI = 95% confidence interval)

^c Month 6 and Month 12 data are mean change from baseline.

Physical Function Response

Improvement in physical functioning was measured by the HAQ-DI. Patients who received tofacitinib 5 mg twice daily demonstrated greater improvement from baseline in physical functioning compared to patients who received placebo at Month 3.

The mean (95% CI) difference from placebo in HAQ-DI improvement from baseline at Month 3 in Study RA-III was -0.22 (-0.35, -0.10) in patients who received 5 mg tofacitinib twice daily. Similar results were obtained in Studies RA-I, II, IV and V. In the 12-month trials, HAQ-DI results in tofacitinib-treated patients were consistent at 6 and 12 months.

Other Health-Related Outcomes

General health status was assessed by the Short Form health survey (SF-36). In Studies RA-I, IV, and V, patients who received tofacitinib 5 mg twice daily demonstrated greater improvement from baseline compared to placebo in physical component summary (PCS), mental component summary (MCS) scores and in all 8 domains of the SF-36 at Month 3.

14.2 Clinical Studies in Psoriatic Arthritis

The psoriatic arthritis (PsA) clinical development program with tofacitinib tablets (referred to as "tofacitinib" in this subsection of labeling) included 2 multicenter, randomized, double-blind, placebo-controlled trials in 816 adults with active PsA (Studies PsA-I and PsA-II).

Trial Designs and Population

All patients had active PsA for at least 6 months based upon the Classification Criteria for Psoriatic Arthritis (CASPAR), at least 3 tender/painful joints and at least 3 swollen joints, and active plaque psoriasis. Patients randomized and treated across the 2 clinical trials represented different PsA subtypes at screening, including < 5 joints or asymmetric involvement (21%), ≥ 5 joints involved (90%), distal interphalangeal (DIP) joint involvement (61%), arthritis mutilans (8%), and spondylitis (19%). Patients in these clinical trials had a diagnosis of PsA for a mean (SD) of 7.7 (7.2) years. At baseline, 80% and 53% of patients had enthesitis and dactylitis, respectively. At baseline, all patients were required to receive treatment with a stable dose of a nonbiologic DMARD (79% received methotrexate, 13% received sulfasalazine, 7% received leflunomide, 1% received other nonbiologic DMARDs). In both clinical trials, the primary endpoints were the ACR20 response and the change from baseline in HAQ-DI at Month 3.

Study PsA-I was a 12-month clinical trial in 422 patients who had an inadequate response to a nonbiologic DMARD (67% and 33% were inadequate responders to 1 nonbiologic DMARD and ≥ 2 nonbiologic DMARDs, respectively) and who were naïve to treatment with a TNF blocker. Although Study PsA-1 included patients who are TNF blocker-naïve, tofacitinib is not approved for use in TNF blocker-naïve patients [see Indications and Usage (1.2)]. Patients were randomized in a 2:2:2:1:1 ratio to receive tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, adalimumab 40 mg subcutaneously once every 2 weeks, placebo to tofacitinib 5 mg twice daily treatment sequence, or placebo to tofacitinib 10 mg twice daily treatment sequence, respectively; study drug was added to background nonbiologic DMARD treatment. At the Month 3 visit, all patients randomized to placebo treatment were switched in a blinded fashion to a predetermined tofacitinib dosage of 5 mg or 10 mg twice daily. Study PsA-I was not designed to demonstrate noninferiority or superiority to adalimumab.

Study PsA-II was a 6-month clinical trial in 394 patients who had an inadequate response to at least 1 approved TNF blocker (66%, 19%, and 15% were inadequate responders to 1 TNF blocker, 2 TNF blockers and ≥ 3 TNF blockers, respectively). Patients were randomized in a 2:2:1:1 ratio to receive tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, placebo to tofacitinib 5 mg twice daily treatment sequence, or placebo to tofacitinib 10 mg twice daily treatment sequence, respectively; study drug was added to background nonbiologic DMARD treatment. At the Month 3 visit, placebo patients were switched in a blinded fashion to a predetermined tofacitinib dosage of 5 mg or 10 mg twice daily as in Study PsA-I. Although other dosages have been studied, the recommended dosage of tofacitinib is 5 mg twice daily. Tofacitinib 10 mg twice daily is not recommended for treatment of PsA [see Dosage and Administration (2.3)].

Clinical Response

At Month 3, patients treated with tofacitinib 5 mg twice daily had higher (p ≤ 0.05) response rates versus placebo for ACR20, ACR50, and ACR70 in Study PsA-I and for ACR20 and ACR50 in Study PsA-II; ACR70 response rates were also higher for tofacitinib 5 mg twice daily versus placebo in Study PsA-II, although the differences versus placebo were not statistically significant (p > 0.05) (Tables 14 and 15).

Treatment Group	Placebo	Tofacitinib 5 mg Twice Daily + Background Nonbiologic DMARD
N^a	105	107
	Response Rate	Response Rate	Difference (%) 95% CI from Placebo
Month 3 ACR20 ACR50 ACR70	33% 10% 5%	50% 28% 17%	17.1 (4.1, 30.2) 18.5 (8.3, 28.7) 12.1 (3.9, 20.2)

Patients with missing data were treated as non-responders.

^* Patients received one concomitant nonbiologic DMARD.

^** Tofacitinib are not approved for use in TNF blocker-naïve patients [see Indications and Usage (1.2)].

^a N is number of randomized and treated patients.

Treatment Group	Placebo	Tofacitinib 5 mg Twice Daily
N^a	131	131
	Response Rate	Response Rate	Difference (%) 95% CI from Placebo
Month 3 ACR20 ACR50 ACR70	24% 15% 10%	50% 30% 17%	26 (14.7, 37.2) 15.3 (5.4, 25.2) 6.9 (-1.3, 15.1)

Patients with missing data were treated as non-responders.

^* Patients received one concomitant nonbiologic DMARD.

^a N is number of randomized and treated patients.

Improvements from baseline in the ACR response criteria components for both studies are shown in Table 16.

	Nonbiologic DMARD Inadequate Responders (TNF Blocker-Naïve)		TNF Blocker Inadequate Responders
	Study PsA-I^,*		Study PsA-II*
Treatment Group	Placebo	Tofacitinib 5 mg Twice Daily	Placebo	Tofacitinib 5 mg Twice Daily
N at Baseline	105	107	131	131
ACR Component^a
Number of tender/painful joints (0-68) Baseline Month 3	20.6 14.6	20.5 12.2	19.8 15.1	20.5 11.5
Number of swollen joints (0-66) Baseline Month 3	11.5 7.1	12.9 6.3	10.5 7.7	12.1 4.8
Patient assessment of arthritis pain^b Baseline Month 3	53.2 44.7	55.7 34.7	54.9 48	56.4 36.1
Patient global assessment of arthritis^b Baseline Month 3	53.9 44.4	54.7 35.5	55.8 49.2	57.4 36.9
HAQ-DI^c Baseline Month 3	1.11 0.95	1.16 0.81	1.25 1.09	1.26 0.88
Physician's Global Assessment of Arthritis^b Baseline Month 3	53.8 35.4	54.6 29.5	53.7 36.4	53.5 27
CRP (mg/L) Baseline Month 3	10.4 8.6	10.5 4	12.1 11.4	13.8 7.7

^* Patients received one concomitant nonbiologic DMARD.

^** Tofacitinib are not approved for use in TNF blocker-naïve patients [see Indications and Usage (1.2)].

^a Data shown are mean value at baseline and at Month 3.

^b Visual analog scale (VAS): 0 = best, 100 = worst.

^c HAQ-DI = Health Assessment Questionnaire – Disability Index: 0 = best, 3 = worst; 20 questions; categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities.

The percentage of ACR20 responders by visit for Study PsA-I is shown in Figure 5. Similar responses were observed in Study PsA-II. In both studies, improvement in ACR20 response on tofacitinib was observed at the first visit after baseline (Week 2).

Figure 5: Percentage of ACR20 Responders by Visit Through Month 3 in Study PsA-I*,**

BID = twice daily; SE = standard error.

Patients with missing data were treated as non-responders.

^* Subjects received one concomitant nonbiologic DMARD.

^** Tofacitinib are not approved for use in TNF blocker-naïve patients [see Indications and Usage (1.2)].

In patients with active PsA evidence of benefit in enthesitis and dactylitis was observed with tofacitinib treatment.

Physical Function

Improvement in physical functioning was measured by the HAQ-DI. Patients receiving tofacitinib 5 mg twice daily demonstrated significantly greater improvement (p ≤ 0.05) from baseline in physical functioning compared to placebo at Month 3 (Table 17).

	Least Squares Mean Change from Baseline In HAQ-DI at Month 3
	Nonbiologic DMARD Inadequate Responders^b (TNF Blocker-Naïve)		TNF Blocker Inadequate Responders^c
	Study PsA-I^,*		Study PsA-II^*
Treatment Group	Placebo	Tofacitinib 5 mg Twice Daily	Placebo	Tofacitinib 5 mg Twice Daily
Na	104	107	131	129
LSM Change from Baseline	-0.18	-0.35	-0.14	-0.39
Difference from Placebo (95% CI)	-	-0.17 (-0.29, -0.05)	-	-0.25 (-0.38, -0.13)

^* Patients received one concomitant nonbiologic DMARD.

^** Tofacitinib are not approved for use in TNF blocker-naïve patients [see Indications and Usage (1.2)].

^a N is the total number of patients in the statistical analysis.

^b Inadequate response to at least one nonbiologic DMARD due to lack of efficacy and/or intolerability.

^c Inadequate response to at least one TNF blocker due to lack of efficacy and/or intolerability.

In Study PsA-I, the HAQ-DI responder rate (response defined as having improvement from baseline of ≥ 0.35) at Month 3 was 53% in patients receiving tofacitinib 5 mg twice daily and 31% in patients receiving placebo. Similar responses were observed in Study PsA-II.

Other Health-Related Outcomes

General health status was assessed by the Short Form health survey (SF-36). In Studies PsA-I and PsA-II, patients receiving tofacitinib 5 mg twice daily had greater improvement from baseline compared to placebo in Physical Component Summary (PCS) score, but not in Mental Component Summary (MCS) score at Month 3. Patients receiving tofacitinib 5 mg twice daily reported consistently greater improvement relative to placebo in the domains of Physical Functioning, Bodily Pain, Vitality, and Social Functioning, but not in Role-Physical, General Health, Role-Emotional, or Mental Health.

Radiographic Response

Treatment effect on inhibition of radiographic progression in PsA could not be established from the results of Study PsA-I.

14.3 Clinical Studies in Ankylosing Spondylitis

The ankylosing spondylitis (AS) clinical development program with tofacitinib tablets (referred to as "tofacitinib" in this subsection of labeling) included one placebo-controlled trial (Study AS-I) in adults with active AS. Patients had active disease as defined by both Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and back pain score (BASDAI question 2) of greater or equal to 4 despite non-steroidal anti-inflammatory drug (NSAID), corticosteroid or disease modifying anti-rheumatic drug (DMARD) therapy.

Trial Design

Study AS-I was a randomized, double-blind, placebo-controlled, 48-week clinical trial in

269 adult patients who had an inadequate response (inadequate clinical response or intolerance) to at least 2 NSAIDs. Although Study AS-I included some patients who are TNF blocker-naïve, tofacitinib are not approved for use in TNF blocker-naïve patients [see Indications and Usage (1.3)]. Patients were randomized and treated with tofacitinib 5 mg twice daily or placebo for 16 weeks of blinded treatment and then all received treatment of tofacitinib 5 mg twice daily for additional 32 weeks. The primary endpoint was to evaluate the proportion of patients who achieved an ASAS20 response at Week 16.

Approximately 7% and 21% of patients used concomitant methotrexate or sulfasalazine, respectively from baseline to Week 16. Twenty-two percent of patients had an inadequate response to 1 or 2 TNF blockers.

Clinical Response

Patients treated with tofacitinib 5 mg twice daily achieved greater improvements in ASAS20 and ASAS40 responses compared to patients treated with placebo at Week 16 (Table 18).

Consistent results were observed in the subgroup of patients who had an inadequate response to TNF blockers for both the ASAS20 (primary endpoint) and ASAS40 (secondary endpoint) at Week 16 (Table 18).

	Placebo	Tofacitinib 5 mg Twice Daily	Difference from Placebo (95% CI)
All patients (N)	N=136	N=133
ASAS20 response*, %	29	56	27 (16, 38)**
ASAS40 response*, %	13	41	28 (18, 38)**
TNFi-IR patients (N)	N=30	N=29
ASAS20 response, %	17	41	25 (2, 47)
ASAS40 response, %	7	28	21 (2, 39)

* type I error-controlled.

** p-value < 0.0001.

Abbreviations: CI = confidence interval; TNFi-IR = tumor necrosis factor inhibitor inadequate response.

The improvements in the components of the ASAS response and other measures of disease activity were greater in the tofacitinib 5 mg twice daily group compared to the placebo group as shown in Table 19.

	Placebo (N=136)		Tofacitinib 5 mg Twice Daily (N=133)
	Baseline	Week 16	Baseline	Week 16	Difference from
	(mean)	(LSM	(mean)	(LSM	Placebo
		change		change	(95% CI)^g
		from		from
		Baseline)^g		Baseline)^g
ASAS Components
- Patient Global Assessment of Disease Activity (0-10)^a,*	7	-1	6.9	-2.5	-1.5 (-2, -0.97)**
- Total spinal pain (0-10)^a,*	6.9	-1.1	6.9	-2.6	-1.5 (-2, -1.03)**
- BASFI (0-10)^b,*	5.9	-0.8	5.8	-2	-1.2 (-1.64, -0.79)**
- Inflammation (0-10)^c,*	6.8	-1.1	6.6	-2.8	-1.7 (-2.13, -1.18)**
BASDAI Score^d	6.5	-1.2	6.4	-2.6	-1.4 (-1.86, -0.98)**
BASMI^e,*	4.4	-0.1	4.5	-0.6	-0.5 (-0.66, -0.36)**
hsCRP^f,* (mg/dL)	1.8	-0.1	1.6	-1.1	-0.9 (-1.17, -0.69)**

* type I error-controlled.

** p < 0.0001.

^a Measured on a numerical rating scale with 0 = not active or no pain, 10 = very active or most severe pain.

^b Bath Ankylosing Spondylitis Functional Index measured on a numerical rating scale with 0 = easy and 10 = impossible.

^c Inflammation is the mean of two patient-reported stiffness self-assessments in BASDAI.

^d BASDAI total score.

^e Bath Ankylosing Spondylitis Metrology Index.

^f High sensitivity C-reactive protein.

^g Estimates are generated based on a mixed model for repeated measures using both on-treatment and off-treatment data.

LSM = least squares mean.

The percentage of patients with active AS who achieved ASAS20 response by visit is shown in Figure 6.

Figure 6: Percentage of ASAS20 Responders Over Time Up to Week 16 in Patients with Active AS in Study AS-I

SE = standard error.

Patients with missing data were treated as non-responders.

Other Health-Related Outcomes

Patients treated with tofacitinib 5 mg twice daily achieved greater improvements from baseline in Ankylosing Spondylitis Quality of Life (ASQoL) (-4 vs -2) compared to patients treated with placebo at Week 16.

14.4 Clinical Studies in Polyarticular Course Juvenile Idiopathic Arthritis

The efficacy of tofacitinib tablets for pcJIA was assessed in Study pcJIA-I (NCT02592434). This was a 44-week, two-part study (that consisted of an 18-week, open-label, run-in phase, followed by a 26-week double-blind, placebo-controlled, randomized withdrawal phase) in pediatric patients 2 years to 17 years of age with active rheumatoid factor (RF) negative polyarthritis, RF positive polyarthritis, extended oligoarthritis, and systemic JIA without systemic manifestations who had an inadequate response or intolerance to at least one DMARD which could have included MTX or biologic agents. This study also included patients ages 2 years to 17 years of age with active juvenile psoriatic arthritis (jPsA) and enthesitis-related arthritis (ERA) who had an inadequate response to NSAIDs. Although the clinical studies included some patients who are TNF blocker-naïve, tofacitinib tablets are not approved for use in TNF blocker-naïve patients [see Indications and Usage (1.4)].

Patients received tofacitinib (dosed at 5 mg twice daily or body weight-based equivalent twice daily) for 18 weeks (run-in phase) followed by randomization to either tofacitinib (dosed at 5 mg twice daily or body weight-based equivalent twice daily) or placebo for 26 weeks (double-blind phase). Only patients who achieved at least a JIA ACR30 response at the end of the run-in phase were randomized (1:1) to the double-blind phase. Treatment with a stable dose of MTX was permitted but was not required during the study. Concurrent use of biologics or DMARDs other than MTX was not permitted in the study.

Baseline Disease Characteristics

A total of 225 pediatric patients with JIA (56 male and 169 female) with active polyarthritis were enrolled in the run-in phase including RF negative (104), RF positive (39), extended oligoarthritis (28), systemic JIA without systemic manifestations (13), jPsA (20), and ERA (21). Patients had a mean (SD) disease duration of 3.8 ± 3.5 years, and a mean (SD) number of active joints of 12.2 ± 8.1.

Efficacy Results

Of the 225 patients, 173 (77%) patients achieved JIA ACR30 response at Week 18 and were randomized into the double-blind phase to either tofacitinib (n=88) or placebo (n=85). At the conclusion of the 18-week, open-label, run-in phase, pediatric ACR 30/50/70 responses were 77%, 70%, and 49%, respectively.

In both the run-in and double-blind phases, approximately one-third of the patients were taking concomitant oral corticosteroids, and approximately two-thirds were taking concomitant MTX.

The primary endpoint was the occurrence of disease flare at Week 44 relative to the double-blind phase baseline at Week 18. Disease flare was defined (according to Pediatric Rheumatology Collaborative Study Group (PRCSG)/Pediatric Rheumatology International Trials Organization (PRINTO) Disease Flare criteria) as worsening of

≥ 30% in 3 or more of the 6 JIA core response variables with no more than 1 of the remaining JIA core response variables improving by ≥ 30%.

Tofacitinib-treated patients experienced significantly fewer disease flares at Week 44 compared to placebo-treated patients (31% [27/88] vs. 55% [47/85]; difference in proportions -25% [95% CI: -39%, -10%]; p=0.0007). The occurrence of disease flare by visit in Study pcJIA-I is shown in Figure 7.

Figure 7: Occurrence of Disease Flare in Pediatric Patients 2 Years of Age and Older with JIA by Visit from Week 18 to Week 44 in the Double-Blind Phase in Study pcJIA-I

BID = twice daily; SE = standard error; N = total number of patients.

The 26-week double-blind phase is from Week 18 through Week 44 on and after randomization day.

14.5 Clinical Studies in Ulcerative Colitis

The efficacy of tofacitinib tablets (referred to as "tofacitinib" in this subsection of labeling) was evaluated in two 12-week induction studies (UC-I and UC-II), a 52-week maintenance study (UC-III), and a long-term extension study (UC-IV).

Induction Trials (Study UC-I [NCT01465763] and Study UC-II [NCT01458951])

In two identical induction trials (UC-I and UC-II), 1139 adult patients were randomized (598 and 541 patients, respectively) to tofacitinib 10 mg twice daily or placebo with a 4:1 treatment allocation ratio. These trials included adult patients with moderately to severely active UC (total Mayo score of 6 to 12, with an endoscopy subscore of at least 2, and rectal bleeding subscore of at least 1) and who had failed or were intolerant to at least 1 of the following treatments: oral or intravenous corticosteroids, azathioprine, 6-MP or TNF blocker. Tofacitinib are indicated only for use in patients who have had inadequate response or intolerance to one or more TNF blockers [see Indications and Usage (1.5)].

The disease activity was assessed by Mayo scoring index (0 to 12) which consists of four subscores (0 to 3 for each subscore): stool frequency, rectal bleeding, findings on endoscopy, and physician global assessment. An endoscopy subscore of 2 was defined by marked erythema, absent vascular pattern, any friability, and erosions; an endoscopy subscore of 3 was defined by spontaneous bleeding and ulceration.

Patients were permitted to use stable doses of oral aminosalicylates and corticosteroids (prednisone daily dose up to 25 mg equivalent). Concomitant immunosuppressants (oral immunomodulators or biologic therapies) were not permitted for UC patients during these studies.

A total of 52%, 73% and 72% of patients had previously failed or were intolerant to TNF blockers (51% in Study UC-1 and 52% in Study UC-II), corticosteroids (75% in Study UC-I and 71% in Study UC-II), and/or immunosuppressants (74% in Study UC-I and 70% in Study UC-II), respectively.

Oral corticosteroids were received as concomitant treatment for UC by 47% of patients (45% in Study UC-I and 48% in Study UC-II) and 71% received concomitant aminosalicylates as treatment for UC (71% in Study UC-I, and 72% in Study UC-II). The baseline clinical characteristics were generally similar between the tofacitinib-treated patients and placebo-treated patients.

The primary endpoint of Study UC-I and Study UC-II was the proportion of patients in remission at Week 8, and the key secondary endpoint was the proportion of patients with improvement of endoscopic appearance of the mucosa at Week 8.

The efficacy results of Study UC-I and Study UC-II based on the centrally read endoscopy results are shown in Table 20.

Study UC-I
Endpoint	Placebo	Tofacitinib 10 mg Twice Daily	Treatment Difference versus Placebo (95% CI)
Remission at Week 8^a
Total Population	N=122	N=476	10%*
	8%	18%	(4.3, 16.3)
With Prior TNF Blocker	N=64	N=243
Failure^b	2%	11%
Without Prior TNF Blocker	N=58	N=233
Failure^c,e	16%	26%
Improvement of Endoscopic Appearance of the Mucosa at Week 8^d
Total Population	N=122	N=476	16%**
	16%	31%	(8.1, 23.4)
With Prior TNF Blocker	N=64	N=243
Failure^b	6%	23%
Without Prior TNF Blocker	N=58	N=233
Failure^c,e	26%	40%
Study UC-II
Endpoint	Placebo	Tofacitinib 10 mg Twice Daily	Treatment Difference (95% CI)
Remission at Week 8^a
Total Population	N=112	N=429	13%**
	4%	17%	(8.1, 17.9)
With Prior TNF Blocker	N=60	N=222
Failure^b	0%	12%
Without Prior TNF Blocker	N=52	N=207
Failure^c,e	8%	22%
Improvement of Endoscopic Appearance of the Mucosa at Week 8^d
Total Population	N=112	N=429	17%**
	12%	28%	(9.5, 24.1)
With Prior TNF Blocker	N=60	N=222
Failure^b	7%	22%
Without Prior TNF Blocker	N=52	N=207
Failure^c,e	17%	36%

* p-value < 0.01, ** p-value < 0.001.

CI = Confidence interval; N = number of patients in the analysis set; TNF = tumor necrosis factor

^a Remission was defined as clinical remission (a Mayo score ≤ 2 with no individual subscore > 1) and rectal bleeding subscore of 0.

^b Prior TNF blocker failure was defined in this program as inadequate response, loss of response, or intolerance to TNF blocker therapy.

^c Patients in this group had failed one or more conventional therapies (corticosteroid, azathioprine, 6-mercaptopurine) but did not have history of prior failure of TNF blocker therapy.

^d Improvement of endoscopic appearance of the mucosa was defined as Mayo endoscopy subscore of 0 (normal or inactive disease) or 1 (erythema, decreased vascular pattern).

^e Tofacitinib tablets indicated only for use in patients who have had inadequate response or intolerance to one or more TNF blockers [see Indications and Usage (1.5)].

Clinical Response at Week 8

Clinical response was defined as a decrease from baseline in Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the subscore for rectal bleeding of ≥ 1 point or absolute subscore for rectal bleeding of 0 or 1.

Clinical response was observed in 60% of patients treated with tofacitinib 10 mg twice daily compared to 33% of patients treated with placebo in Study UC-I and 55% compared to 29% in Study UC-II.

Normalization of the Endoscopic Appearance of the Mucosa at Week 8

Normalization of endoscopic appearance of the mucosa was defined as a Mayo endoscopic subscore of 0 and was observed in 7% of patients treated with tofacitinib 10 mg twice daily compared to 2% of treated with placebo in both Studies UC-I and UC-II.

Rectal Bleeding and Stool Frequency

Decreases in rectal bleeding and stool frequency subscores were observed as early as Week 2 in patients treated with tofacitinib.

Maintenance Trial (Study UC-III [NCT01458574])

A total of 593 adult patients who completed the induction trials (UC-I or UC-II) and achieved clinical response were re-randomized with 1:1:1 treatment allocation ratio to tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, or placebo for 52 weeks in Study UC-III. tofacitinib 5 mg twice daily is the recommended dosage for maintenance therapy; limit use of tofacitinib 10 mg twice daily beyond induction to those with loss of response and should be used for the shortest duration [see Dosage and Administration (2.5)]. As in the induction trials, patients were permitted to use stable doses of oral aminosalicylates; however, corticosteroid tapering was required upon entrance into this study for patients who were receiving corticosteroids at baseline. Concomitant immunosuppressants (oral immunomodulators or biologic therapies) were not permitted.

At baseline of Study UC-III:

179 (30%) patients were in remission 289 (49%) patients were receiving oral corticosteroids 265 (45%), 445 (75%), and 413 (70%) patients had previously failed or were intolerant to TNF blocker therapy, corticosteroids, and immunosuppressants, respectively. Tofacitinib tablet is indicated only for use in patients who have had inadequate response or intolerance to one or more TNF blockers [see Indications and Usage (1.5)]. In Study UC-III, the primary endpoint was the proportion of patients in remission at Week 52. There were two key secondary endpoints: the proportion of patients with improvement of endoscopic appearance at Week 52, and the proportion of patients with sustained corticosteroid-free remission at both Week 24 and Week 52 among patients in remission at baseline of Study UC-III.

The efficacy results of Study UC-III based on the centrally read endoscopy results are summarized in Table 21.

				Treatment Difference versus Placebo (95% CI)
Endpoint	Placebo	Tofacitinib 5 mg Twice Daily	Tofacitinib 10 mg Twice Daily	Tofacitinib 5 mg Twice Daily	Tofacitinib 10 mg Twice Daily
Remission at Week 52^a
Total Population	N=198	N=198	N=197	23%* (15.3, 31.2)	30%* (21.4, 37.6)
	11%	34%	41%
With Prior TNF Blocker Failure^b	N=89	N=83	N=93
	11%	24%	37%
Without Prior TNF Blocker Failure^c,f	N=109	N=115	N=104
	11%	42%	44%
				Treatment Difference versus Placebo (95% CI)
Endpoint	Placebo	Tofacitinib 5 mg Twice Daily	Tofacitinib 10 mg Twice Daily	Tofacitinib 5 mg Twice Daily	Tofacitinib 10 mg Twice Daily
Improvement of endoscopic appearance of the mucosa at Week 52^d
Total Population	N=198	N=198	N=197	24%* (16, 32.5)	33%* (24.2, 41)
	13%	37%	46%
With Prior TNF Blocker Failure^b	N=89	N=83	N=93
	12%	30%	40%
Without Prior TNF Blocker Failure^c,f	N=109	N=115	N=104
	14%	43%	51%
Sustained corticosteroid-free remission at both Week 24 and Week 52 among patients in remission at baseline^e
Total Population	N=59	N=65	N=55	30%* (17.4, 43.2)	42%* (27.9, 56.5)
	5%	35%	47%
With Prior TNF Blocker Failure^b	N=21	N=18	N=18
	5%	22%	39%
Without Prior TNF Blocker Failure^c,f	N=38	N=47	N=37
	5%	40%	51%

* p-value < 0.0001.

CI = Confidence interval; N = number of patients in the analysis set; TNF = tumor necrosis factor.

^a Remission was defined as clinical remission (a Mayo score ≤ 2 with no individual subscore > 1) and rectal bleeding subscore of 0.

^b Prior TNF blocker failure was defined in this program as inadequate response, loss of response, or intolerance to TNF blocker therapy.

^c Patients in this group had failed one or more conventional therapies (corticosteroid, azathioprine, 6-mercaptopurine) but did not have history of prior failure of TNF blocker therapy.

^d Improvement of endoscopic appearance of the mucosa was defined as Mayo endoscopy subscore of 0 (normal or inactive disease) or 1 (erythema, decreased vascular pattern).

^e Sustained corticosteroid-free remission was defined as being in remission and not taking corticosteroids for at least 4 weeks prior to the visit at both Week 24 and Week 52.

^f Tofacitinib tablets are indicated only for use in patients who have had inadequate response or intolerance to one or more TNF blockers [see Indications and Usage (1.5)].

Maintenance of Clinical Response

Maintenance of clinical response was defined as the proportion of patients who met the definition of clinical response (defined as a decrease from the induction study (UC-I, UC-II) baseline Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or rectal bleeding subscore of 0 or 1) at both Baseline and Week 52 of Study UC-III.

Maintenance of clinical response was observed in 20% in the placebo group, 52% in the tofacitinib 5 mg twice daily group, and 62% in the tofacitinib 10 mg twice daily group.

Maintenance of Remission (Among Patients in Remission at Baseline)

In the 179 patients who were in remission at baseline of Study UC-III (N = 59 for placebo, N = 65 for tofacitinib 5 mg twice daily, N = 55 for tofacitinib 10 mg twice daily), 10% in the placebo group, 46% in the tofacitinib 5 mg twice daily group and 56% in the tofacitinib 10 mg twice daily group maintained remission at Week 52.

Normalization of the Endoscopic Appearance of the Mucosa

Normalization of endoscopic appearance of the mucosa was defined as a Mayo endoscopic subscore of 0 and was observed at Week 52 in 15% of patients in the tofacitinib 5 mg twice daily group and 17% of patients in the tofacitinib 10 mg twice daily group compared to 4% of placebo patients.

Open-label Extension Study (Study UC-IV [NCT01470612])

In Study UC-IV, 914 patients were treated of which 156 received tofacitinib 5 mg twice daily and 758 received tofacitinib 10 mg twice daily.

Of the 905 patients who were assigned to tofacitinib 10 mg twice daily in the 8-week induction studies (Study UC-I or Study UC-II), 322 patients completed the induction studies but did not achieve clinical response. Of these 322 patients, 291 continued to receive tofacitinib 10 mg twice daily (unblinded) and had available data after an additional 8 weeks in Study UC-IV. After 8 additional weeks (a total of 16 weeks treatment), 148 patients achieved clinical response, and 25 patients achieved remission (based on central endoscopy read). Among those 143 patients who achieved clinical response by 16 weeks and had available data at Week 52, 66 patients achieved remission (based on local endoscopy read) after continued treatment with tofacitinib 10 mg twice daily for 52 weeks.

14.6 Safety Study in Adults with Rheumatoid Arthritis (Tofacitinib Versus TNF-blocker)

A randomized open-label trial (RA Safety Study 1; NCT02092467) was conducted to evaluate safety with tofacitinib tablets (referred to as "tofacitinib" in this subsection of labeling) at two doses, 5 mg twice daily (N=1455) and 10 mg twice daily (N=1456), versus the TNF-blocker control (N=1451) in RA patients 50 years of age and older with at least one cardiovascular risk factor. The co-primary endpoints were adjudicated MACE (defined as cardiovascular death, non-fatal MI, and non-fatal stroke) and adjudicated malignancy (excluding non-melanoma skin cancer). The study was designed to exclude a prespecified risk margin of 1.8 for the hazard ratio of combined tofacitinib regimens versus the TNF-blocker control for each co-primary endpoint. An independent committee conducted a blinded evaluation of the co-primary endpoints according to predefined criteria (adjudication). The study was event-driven and patients were followed until a sufficient number of primary outcome events accrued. Other endpoints included mortality, serious infections, and thromboembolic events. The median on-study follow-up time was 4 years.

The mean age of the population was 61 years (range: 50 to 88 years). Most patients were female (78%) and Caucasian (77%). Patients had a diagnosis of RA for a mean of 10 years, and a median swollen and tender joint count of 11 and 15 respectively. Cardiovascular risk factors included cigarette smoking (current or past) (48%), hypertension (66%), high density lipoprotein < 40 mg/dL (12%), diabetes mellitus (17%), family history of premature coronary heart disease (15%), extra-articular disease associated with RA (37%), and history of coronary artery disease (11%).

The non-inferiority criterion was not met for the primary comparison of the combined tofacitinib dosages to TNF blockers since the upper limit of the 95% CI exceeded the pre-specified non-inferiority criterion of 1.8 (for MACE, the upper limit of the 95% CI was 1.94; for malignancies excluding NMSC, the upper limit of the 95% CI was 2.09).

Table 22 shows the study results for each of the co-primary endpoints, and other endpoints. There was an increased risk of death, MACE, malignancies, serious infections, thromboembolic events, and fractures associated with both dosages of tofacitinib.

Endpoint	TNF Blocker N=1,451 PY=5,526	Tofacitinib 5 mg Twice Daily N=1,455 PY=5,551	Tofacitinib 10 mg Twice Daily N=1,456 PY=5,371
MACE, n [IR] HR (95% CI)*	43 [0.79]	50 [0.91] 1.16 (0.77, 1.74)	59 [1.11] 1.41 (0.95, 2.10)
MI,^† n [IR] HR (95% CI)*	11 [0.20]	20 [0.36] 1.81 (0.87, 3.79)	21 [0.39] 1.97 (0.95, 4.09)
Stroke,^† n [IR] HR (95% CI)*	20 [0.36]	18 [0.33] 0.89 (0.47, 1.69)	21 [0.39] 1.08 (0.59, 2)
Cardiovascular Death, n [IR] HR (95% CI)*	15 [0.27]	18 [0.32] 1.20 (0.60, 2.37)	25 [0.47] 1.71 (0.90, 3.24)
Malignancies Excl. NMSC, n [IR] HR (95% CI)*	42 [0.77]	62 [1.13] 1.47 (1, 2.18)	60 [1.13] 1.48 (1, 2.19)
Malignancies Excl. NMSC (among current and past smokers)^††	25 [0.99]	41 [1.53]	48 [1.91]
HR (95% CI)*		1.55 (0.94, 2.55)	1.94 (1.19, 3.14)
All Death HR (95% CI)*	38 [0.69]	49 [0.88] 1.29 (0.84, 1.96)	66 [1.23] 1.79 (1.20, 2.66)
Serious Infections HR (95% CI)*	133 [2.52]	155 [2.95] 1.17 (0.93, 1.47)	184 [3.65] 1.44 (1.15, 1.80)
DVT HR (95% CI)*	9 [0.16]	12 [0.22] 1.33 (0.56, 3.15)	15 [0.28] 1.72 (0.75, 3.92)
PE HR (95% CI)*	3 [0.05]	10 [0.18] 3.32 (0.91, 12.08)	26 [0.49] 8.95 (2.71, 29.56)
VTE HR (95% CI)*	12 [0.22]	18 [0.33] 1.50 (0.72, 3.10)	36 [0.68] 3.10 (1.61, 5.96)
ATE HR (95% CI)*	45 [0.83]	51 [0.93] 1.13 (0.76, 1.69)	55 [1.04] 1.26 (0.85, 1.87)
TE HR (95% CI)*	56 [1.03]	67 [1.23] 1.19 (0.84, 1.70)	86 [1.65] 1.60 (1.14, 2.23)
All Fractures HR (95% CI)*	121 [2.32]	138 [2.64] 1.14 (0.90, 1.46)	141 [2.80] 1.21 (0.95, 1.54)
Osteoporotic Fractures HR (95% CI)*	49 [0.91]	58 [1.07] 1.18 (0.81, 1.73)	70 [1.34] 1.48 (1.03, 2.13)

Note: Tofacitinib 10 mg twice daily was discontinued by the Data Monitoring Committee due to safety concerns, and ongoing patients switched from tofacitinib 10 mg to tofacitinib 5 mg. The column "tofacitinib 10 mg Twice Daily" includes all events and follow-up for patients randomized to tofacitinib 10 mg twice daily. A tofacitinib (refers to tablets) 10 mg twice daily dosage is not recommended for the treatment of RA, PsA, AS, or pcJIA [see Dosage and Administration (2.3)].

N indicates number of patients; n indicates number of patients with events. IR indicates incidence rate per 100 person-year (PY).

†MI and Stroke include fatal and non-fatal events.

††Data and analyses for Malignancies excluding NMSC for current and ex-smokers are included. There were 720 current and ex-smokers randomized to tofacitinib 5 mg, 704 to tofacitinib 10 mg, and 679 to TNF blockers.

*HR (95%) CI for tofacitinib vs. TNF Blocker (Univariate Cox Proportional Hazard Model).

NMSC: Non-melanoma Skin Cancer; MACE: Major Adverse Cardiac Events; HR: Hazard Ratio; DVT: Deep Vein Thrombosis; PE: Pulmonary Embolism; VTE: Venous Thromboembolism, first occurrence of a VTE, defined as the composite of adjudicated DVT and adjudicated PE; ATE: Arterial Thromboembolism; TE: Thromboembolism, first occurrence of a TE, defined as the composite of adjudicated VTE and unadjudicated ATE.

Lymphomas and lung cancers, which are a subset of all malignancies in RA Safety Study 1, were observed at a higher rate in patients treated with tofacitinib 5 mg twice a day and tofacitinib 10 mg twice a day compared to those treated with TNF blockers. Lymphoma was reported for 4 patients who received tofacitinib 5 mg twice a day, 6 patients who received tofacitinib 10 mg twice a day, and 1 patient who received TNF blockers (Incidence Rate [IR] of 0.07, 0.11, and 0.02 per 100 patient-years, respectively). Among current and past smokers, lung cancer was reported for 13 patients who received tofacitinib 5 mg twice a day, 15 patients who received tofacitinib 10 mg twice a day, and 7 patients who received TNF blockers (IR of 0.48, 0.59, and 0.27 per 100 patient-years, respectively).

Given these increased risks, tofacitinib tablets 10 mg twice daily dosages are not recommended for the treatment of RA, PsA, AS or pcJIA [see Dosage and Administration (2.3, 2.4)].

The overall fractures and osteoporotic fractures were observed at a higher rate in both tofacitinib treatment groups compared to the TNF blocker treatment group. The observed incidence rate of osteoporotic fractures was higher in women than men, and was highest in women on tofacitinib 10 mg twice daily (1.56 per 100

patient-years), followed by tofacitinib 5 mg twice daily (1.26 per 100 patient-years), and TNF blockers (1.01 per 100 patient-years).

16 HOW SUPPLIED/STORAGE AND HANDLING

Tofacitinib tablets, 5 mg (equivalent to 8.08 mg tofacitinib citrate) are white to off white

colored, round, film-coated tablets, debossed with "1243" on one side and plain on the

other side and supplied as follows:

NDC 70710-1243-6 in bottle of 60 tablets with child-resistant closure.

NDC 70710-1243-8 in bottle of 180 tablets with child-resistant closure.

Tofacitinib tablets, 10 mg (equivalent to 16.15 mg tofacitinib citrate) are light green to

green colored, round shaped, film coated tablets debossed with "1589" on one side and

plain on the other side and supplied as follows:

NDC 70710-1589-7 in bottle of 28 tablets with child-resistant closure.

NDC 70710-1589-6 in bottle of 60 tablets with child-resistant closure.

NDC 70710-1589-8 in bottle of 180 tablets with child-resistant closure.

Store tofacitinib tablets at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (between 59°F and 86°F) [see USP Controlled Room Temperature].

Do not repackage.

17 PATIENT COUNSELING INFORMATION

Advise patients to read the FDA-approved patient labeling (Medication Guide).

Serious Infections

Inform patients that tofacitinib tablets may lower the ability of their immune system to fight infections. Advise patients not to start taking tofacitinib tablets if they have an active infection. Instruct patients to contact their healthcare provider immediately during treatment if symptoms suggesting infection appear to ensure rapid evaluation and appropriate treatment [see Warnings and Precautions (5.1)].

Advise patients that the risk of herpes zoster, some cases of which can be serious, is increased in patients treated with tofacitinib tablets [see Warnings and Precautions (5.1)].

Malignancies and Lymphoproliferative Disorders

Inform patients that tofacitinib tablets may increase their risk of certain cancers, and that lymphoma and other cancers have been observed in patients taking tofacitinib tablets. Instruct patients to inform their healthcare provider if they have ever had any type of cancer [see Warnings and Precautions (5.3)].

Major Adverse Cardiovascular Events

Inform patients that tofacitinib tablets may increase their risk of major adverse cardiovascular events (MACE) defined as myocardial infarction, stroke, and cardiovascular death. Instruct all patients, especially current or past smokers or patients with other cardiovascular risk factors, to be alert for the development of signs and symptoms of cardiovascular events [see Warnings and Precautions (5.4)].

Thrombosis

Advise patients to stop taking tofacitinib tablets and to call their healthcare provider right away if they experience any symptoms of thrombosis (sudden shortness of breath, chest pain worsened with breathing, swelling of leg or arm, leg pain or tenderness, red or discolored skin in the affected leg or arm) [see Warnings and Precautions (5.5)].

Hypersensitivity

Advise patients to stop taking tofacitinib tablets and to call their healthcare provider right away if they experience any symptoms of allergic reactions while taking tofacitinib tablets [see Warnings and Precautions (5.7)].

Important Information on Laboratory Abnormalities

Inform patients that tofacitinib tablets may affect certain lab test results, and that blood tests are required before and during tofacitinib tablets treatment [see Warnings and Precautions (5.8)].

Pregnancy

Advise pregnant females and females of reproductive potential of the potential risk to a fetus. Advise females to inform their prescriber of a known or suspected pregnancy [see Use in Specific Populations (8.1)].

Lactation

Advise women not to breastfeed during treatment with tofacitinib tablets and for at least 18 hours after the last dose of tofacitinib tablets [see Use in Specific Populations (8.2)].

Infertility

Advise females of reproductive potential that tofacitinib tablets may impair fertility [see Use in Specific Populations (8.3), Nonclinical Toxicology (13.1)]. It is not known if this effect is reversible.

XELJANZ and XELJANZ XR are registered trademarks of Pfizer Inc.

All trademarks are the property of their respective owners.

SPL UNCLASSIFIED

Manufactured by

Zydus Lifesciences Ltd.

Ahmedabad, India

Distributed by

Zydus Pharmaceuticals (USA) Inc.

Pennington, NJ 08534

Rev.: 05/26

SPL MEDGUIDE

MEDICATION GUIDE Tofacitinib (toe" fa sye' ti nib) Tablets
What is the most important information I should know about tofacitinib tablets? Tofacitinib tablets may cause serious side effects including: 1. Serious infections. Tofacitinib tablet is medicines that affect your immune system. Tofacitinib tablets can lower the ability of your immune system to fight infections. Some people can have serious infections while taking tofacitinib tablets, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider should test you for TB before starting tofacitinib tablets and during treatment. Your healthcare provider should monitor you closely for signs and symptoms of TB infection during treatment with tofacitinib tablets. You should not start taking tofacitinib tablets if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster). People with ulcerative colitis taking the higher dose of tofacitinib (10 mg twice daily) have a higher risk of serious infections and shingles. Before starting tofacitinib tablets, tell your healthcare provider if you: think you have an infection or have symptoms of an infection such as:
fever, sweating, or chills	muscle aches
cough	shortness of breath
blood in phlegm	weight loss
warm, red, or painful skin or sores on your body	diarrhea or stomach pain
burning when you urinate or urinating more often than normal	feeling very tired
are being treated for an infection. get a lot of infections or have infections that keep coming back. have diabetes, chronic lung disease, HIV, or a weak immune system. People with these conditions have a higher chance for infections. have TB, or have been in close contact with someone with TB. live or have lived, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections (histoplasmosis, coccidioidomycosis, or blastomycosis). These infections may happen or become more severe if you take tofacitinib tablets. Ask your healthcare provider if you do not know if you have lived in an area where these infections are common. have or have had hepatitis B or C. After starting tofacitinib tablets, call your healthcare provider right away if you have any symptoms of an infection. Tofacitinib tablets can make you more likely to get infections or make worse any infection that you have. 2. Increased risk of death in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking tofacitinib 5 mg or 10 mg twice daily. 3. Cancer and immune system problems. Tofacitinib tablets may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers including skin cancers can happen in people taking tofacitinib tablets. People taking tofacitinib 5 mg twice daily or tofacitinib 10 mg twice daily have a higher risk of certain cancers including lymphoma and lung cancer, especially if you are a current or past smoker. People with ulcerative colitis taking the higher dose of tofacitinib (10 mg twice daily) or have a higher risk of skin cancers. Tell your healthcare provider if you have ever had any type of cancer. 4. Increased risk of major cardiovascular events such as heart attack, stroke or death in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking tofacitinib 5 mg or 10 mg twice daily, especially if you are a current or past smoker . Get emergency help right away if you have any symptoms of a heart attack or stroke while taking tofacitinib tablets, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw pain or discomfort in your arms, back, neck, jaw, or stomach shortness of breath with or without chest discomfort breaking out in a cold sweat nausea or vomiting feeling lightheaded weakness in one part or on one side of your body slurred speech 5. Blood clots in the lungs, veins of the legs or arms, and arteries. Blood clots in the lungs (pulmonary embolism, PE), veins of the legs (deep vein thrombosis, DVT) and arteries (arterial thrombosis) have happened more often in people who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking tofacitinib 5 mg or 10 mg twice daily. Blood clots in the lungs have also happened in people with ulcerative colitis. Some people have died from these blood clots. Stop taking tofacitinib tablets and tell your healthcare provider right away if you develop signs and symptoms of a blood clot, such as sudden shortness of breath or difficulty breathing, chest pain, swelling of the leg or arm, leg pain or tenderness, or redness or discoloration in the leg or arm. 6. Tears (perforation) in the stomach or intestines. Tell your healthcare provider if you have had diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines. Some people taking tofacitinib tablets can get tears in their stomach or intestines. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. Tell your healthcare provider right away if you have fever and stomach-area pain that does not go away, and a change in your bowel habits. 7. Allergic reactions. Symptoms such as swelling of your lips, tongue, or throat, or hives (raised, red patches of skin that are often very itchy) that may mean you are having an allergic reaction have been seen in people taking tofacitinib tablets. Some of these reactions were serious. If any of these symptoms occur while you are taking tofacitinib tablets, stop tofacitinib tablets and call your healthcare provider right away. 8. Changes in certain laboratory test results. Your healthcare provider should do blood tests before you start taking tofacitinib tablets and while you take tofacitinib tablets to check for the following side effects: changes in lymphocyte counts. Lymphocytes are white blood cells that help the body fight off infections. low neutrophil counts. Neutrophils are white blood cells that help the body fight off infections. low red blood cell count. This may mean that you have anemia, which may make you feel weak and tired. Your healthcare provider should routinely check certain liver tests. You should not take tofacitinib tablets if your lymphocyte count, neutrophil count, or red blood cell count is too low or your liver tests are too high. Your healthcare provider may stop your tofacitinib tablets treatment for a period of time if needed because of changes in these blood test results. You may also have changes in other laboratory tests, such as your blood cholesterol levels. Your healthcare provider should do blood tests to check your cholesterol levels 4 to 8 weeks after you start taking tofacitinib tablets, and as needed after that. Normal cholesterol levels are important to good heart health. See " What are the possible side effects of tofacitinib tablets? " for more information about side effects.
What are tofacitinib tablets? Tofacitinib tablets are a prescription medicine called a Janus kinase (JAK) inhibitor. tofacitinib tablets are used to treat adults with moderately to severely active rheumatoid arthritis when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used and did not work well or cannot be tolerated. Tofacitinib tablets are used to treat adults and children 2 years of age and older with active psoriatic arthritis when 1 or more TNF blocker medicines have been used, and did not work well or cannot be tolerated. Tofacitinib tablets are used to treat adults with active ankylosing spondylitis when 1 or more TNF blocker medicines have been used and did not work well or cannot be tolerated. Tofacitinib tablets are used to treat adults with moderately to severely active ulcerative colitis when 1 or more TNF blocker medicines have been used, and did not work well or cannot be tolerated. Tofacitinib tablets are used to treat children 2 years of age and older with active polyarticular course juvenile arthritis when 1 or more TNF blocker medicines have been used, and did not work well or cannot be tolerated. It is not known if tofacitinib tablets are safe and effective in people with Hepatitis B or C. Tofacitinib tablets are not recommended for people with severe liver problems. It is not known if tofacitinib tablets are safe and effective in children for treatment other than active polyarticular course juvenile arthritis and psoriatic arthritis.
What should I tell my healthcare provider before taking tofacitinib tablets? Before taking tofacitinib tablets, tell your healthcare provider about all of your medical conditions, including if you: have an infection. See "What is the most important information I should know about tofacitinib tablets?" are a current or past smoker. have had any type of cancer. have had a heart attack, other heart problems or stroke. have had blood clots in the veins of your legs, arms, or lungs, or clots in the arteries in the past. have liver problems. have kidney problems. have any stomach-area (abdominal) pain or been diagnosed with diverticulitis or ulcers in your stomach or intestines. have had a reaction to tofacitinib or any of the ingredients in tofacitinib tablets. have recently received or are scheduled to receive a vaccine. People who take tofacitinib tablets should not receive live vaccines. People taking tofacitinib tablets can receive non-live vaccines. plan to become pregnant or are pregnant. Tofacitinib tablets may affect the ability of females to get pregnant. It is not known if this will change after stopping tofacitinib tablets. It is not known if tofacitinib tablets will harm an unborn baby. plan to breastfeed or are breastfeeding. You and your healthcare provider should decide if you will take tofacitinib tablets or breastfeed. You should not do both. After you stop your treatment with tofacitinib tablets do not start breastfeeding again until: o 18 hours after your last dose of tofacitinib tablets Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tofacitinib tablets and other medicines may affect each other causing side effects. Especially tell your healthcare provider if you take : any other medicines to treat your rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, or polyarticular course juvenile arthritis. You should not take tocilizumab (Actemra), etanercept (Enbrel), adalimumab (Humira), infliximab (Remicade), rituximab (Rituxan), abatacept (Orencia), anakinra (Kineret), certolizumab (Cimzia), golimumab (Simponi), ustekinumab (Stelara), secukinumab (Cosentyx), vedolizumab (Entyvio), ixekizumab (Taltz), azathioprine, cyclosporine, or other immunosuppressive drugs while you are taking tofacitinib tablets. Taking tofacitinib tablets with these medicines may increase your risk of infection. medicines that affect the way certain liver enzymes work. Ask your healthcare provider if you are not sure if your medicine is one of these. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
How should I take tofacitinib tablets? Take tofacitinib tablets exactly as your healthcare provider tells you to take it. Take tofacitinib tablets 2 times a day with or without food. If you take too much tofacitinib tablets, call your healthcare provider or go to the nearest hospital emergency room right away. For the treatment of psoriatic arthritis, take tofacitinib tablets in combination with methotrexate, sulfasalazine or leflunomide as instructed by your healthcare provider.
What are the possible side effects of tofacitinib tablets? tofacitinib tablets may cause serious side effects, including: See "What is the most important information I should know about tofacitinib tablets?" Hepatitis B or C activation infection in people who carry the virus in their blood. If you are a carrier of the hepatitis B or C virus (viruses that affect the liver), the virus may become active while you use tofacitinib tablets. Your healthcare provider may do blood tests before you start treatment with tofacitinib tablets and while you are taking tofacitinib tablets. Tell your healthcare provider if you have any of the following symptoms of a possible hepatitis B or C infection:
feel very tired	skin or eyes look yellow
little or no appetite	vomiting
clay-colored bowel movements	fevers
chills	stomach discomfort
muscle aches	dark urine
skin rash
Common side effects of tofacitinib tablets in people with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis include: upper respiratory tract infections (common cold, sinus infections) headache diarrhea nasal congestion, sore throat, and runny nose (nasopharyngitis) high blood pressure (hypertension) acne Common side effects of tofacitinib tablets in people with ulcerative colitis include: nasal congestion, sore throat, and runny nose (nasopharyngitis) increased cholesterol levels headache upper respiratory tract infections (common cold, sinus infections) increased muscle enzyme levels rash acne diarrhea shingles (herpes zoster) Common side effects of tofacitinib tablets in children with polyarticular course juvenile arthritis and psoriatic arthritis include: upper respiratory tract infections (common cold, sinus infections) nasal congestion, sore throat, and runny nose (nasopharyngitis) headache fever nausea vomiting acne Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of tofacitinib tablets. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Zydus Pharmaceuticals (USA) Inc. at 1-877-993-8779.
How should I store tofacitinib tablets? Store tofacitinib tablets at room temperature between 68°F to 77°F (20°C to 25°C) [see USP Controlled Room Temperature]. Tofacitinib tablets come in a child-resistant package. Keep tofacitinib tablets and all medicines out of the reach of children.
General information about the safe and effective use of tofacitinib tablets. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use tofacitinib tablets for a condition for which it was not prescribed. Do not give tofacitinib tablets to other people, even if they have the same symptoms you have. It may harm them. This Medication Guide summarizes the most important information about tofacitinib tablets. If you would like more information, talk to your healthcare provider. You can ask your pharmacist or healthcare provider for information about tofacitinib tablets that is written for health professionals.
What are the ingredients in tofacitinib tablets? Active ingredient: tofacitinib citrate Inactive ingredients: croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone and titanium dioxide. Additionally, each 10 mg tablet contains FD&C blue #1 Aluminum Lake and iron oxide yellow. XELJANZ and XELJANZ XR are registered trademarks of Pfizer Inc. All trademarks are the property of their respective owners.
Manufactured by Zydus Lifesciences Ltd. Ahmedabad, India Distributed by Zydus Pharmaceuticals (USA) Inc. Pennington, NJ 08534
Rev.: 05/26

This Medication Guide has been approved by the U.S. Food and Drug Administration.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Tofacitinib Tablets, 5 mg

NDC 70710-1243-6

60 Tablets

Rx only

Zydus

Tofacitinib Tablets, 10 mg

NDC 70710-1589-6

60 Tablets

Rx only

Zydus

Tofacitinib 5 Mg (as Tofacitinib Citrate 8 Mg) Oral Tablet

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS

RECENT MAJOR CHANGES

1 INDICATIONS AND USAGE

1.1 Rheumatoid Arthritis

1.2 Psoriatic Arthritis

1.3 Ankylosing Spondylitis

1.4 Polyarticular Course Juvenile Idiopathic Arthritis

1.5 Ulcerative Colitis

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Evaluations and Immunization Prior to Treatment Initiation

2.2 Important Administration Instructions

2.3 Recommended Dosage in Adults with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

2.4 Recommended Dosage in Pediatric Patients 2 Years of Age and Older with Psoriatic Arthritis or Polyarticular Course Juvenile Idiopathic Arthritis

2.5 Recommended Dosage in Adults with Ulcerative Colitis

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Serious Infections

5.2 Increased Risk of Mortality

5.3 Malignancy and Lymphoproliferative Disorders

5.4 Major Adverse Cardiovascular Events

5.5 Thrombosis

5.6 Gastrointestinal Perforations

5.7 Hypersensitivity Reactions

5.8 Laboratory Abnormalities

5.9 Vaccinations

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

6.2 Postmarketing Experience

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

8.3 Females and Males of Reproductive Potential

8.4 Pediatric Use

8.5 Geriatric Use

8.6 Renal Impairment

8.7 Hepatic Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

14.1 Clinical Studies in Rheumatoid Arthritis

14.2 Clinical Studies in Psoriatic Arthritis

14.3 Clinical Studies in Ankylosing Spondylitis

14.4 Clinical Studies in Polyarticular Course Juvenile Idiopathic Arthritis

14.5 Clinical Studies in Ulcerative Colitis

14.6 Safety Study in Adults with Rheumatoid Arthritis (Tofacitinib Versus TNF-blocker)

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

SPL UNCLASSIFIED

SPL MEDGUIDE

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL